{"content":"<li class=\"n-box-item date-title\" data-end=\"1545368399\" data-start=\"1545282000\" data-txt=\"Monday, December 23, 2019\">Thursday, December 20, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3418707\" data-ts=\"1545346145\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418707-nke-cgc-camp-and-stmp-among-after-hours-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NKE, CGC, CAMP and STMP among after hours movers</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color=\"green\">+8.7%</font>. <a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color=\"green\">+5.8%</font>.<a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color=\"green\">+5.2%</font>. <a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color=\"green\">+5.1%</font>. <a href='https://seekingalpha.com/symbol/IGT' title='International Game Technology'>IGT</a> <font color=\"green\">+5.1%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color=\"red\">-17%</font>. <a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a> <font color=\"red\">-8.9%</font>. <a href='https://seekingalpha.com/symbol/UXIN' title='Uxin'>UXIN</a> <font color=\"red\">-5.3%</font>. <a href='https://seekingalpha.com/symbol/STMP' title='Stamps.com Inc.'>STMP</a> <font color=\"red\">-2.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418707\" data-linked=\"NKE, CGC, CAMP and STMP among after hours movers\" data-tweet=\"$NKE $NKE $CGC - NKE, CGC, CAMP and STMP among after hours movers https://seekingalpha.com/news/3418707-nke-cgc-camp-and-stmp-among-after-hours-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418707-nke-cgc-camp-and-stmp-among-after-hours-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418706\" data-ts=\"1545345367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRTS\" target=\"_blank\">GRTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418706-gritstoneplus-10-after-colorectal-cancer-treatment-gets-fast-track-status\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gritstone +10% after colorectal cancer treatment gets Fast-Track status</a></h4><ul><li>Gritstone Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/GRTS' title='Gritstone Oncology'>GRTS</a>) <font color=\"green\">jumps 10%</font> in after-hours trading after its Granite-001 treatment for colorectal cancer<a href=\"https://seekingalpha.com/pr/17364856-gritstone-oncology-announces-fda-fast-track-designation-graniteminus-001-treatment-colorectal\" target=\"_blank\"> is granted</a> Fast-Track status by the U.S. Food and Drug Administration.</li><li>A therapeutic that gets a Fast-Track designation can benefit from early and frequent communication with the FDA, in addition to a rolling submission of the marketing application, with the objective of getting new therapies to patients more quickly.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3415610-gritstone-oncology-names-head-bispecific-antibody-program\" target=\"_blank\">Gritstone Oncology names head of bispecific antibody program</a> (Dec. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418706\" data-linked=\"Gritstone +10% after colorectal cancer treatment gets Fast-Track status\" data-tweet=\"$GRTS - Gritstone +10% after colorectal cancer treatment gets Fast-Track status https://seekingalpha.com/news/3418706-gritstoneplus-10-after-colorectal-cancer-treatment-gets-fast-track-status?source=tweet\" data-url=\"https://seekingalpha.com/news/3418706-gritstoneplus-10-after-colorectal-cancer-treatment-gets-fast-track-status\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418702\" data-ts=\"1545344543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418702-canopy-growth-ready-for-u-s-move-shares-up-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canopy Growth ready for U.S. move, shares up 7%</a></h4><ul><li>Following the president's signing of the Farm Bill, which includes the Hemp Farming Act, Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) announces its intention to move into the U.S. market.</li><li>Shares <font color=\"green\">up 7.5%</font> after hours</li><li>Source: <a href=\"https://seekingalpha.com/pr/17364971-canopy-growth-comments-farm-bill\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418702\" data-linked=\"Canopy Growth ready for U.S. move, shares up 7%\" data-tweet=\"$CGC - Canopy Growth ready for U.S. move, shares up 7% https://seekingalpha.com/news/3418702-canopy-growth-ready-for-u-s-move-shares-up-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3418702-canopy-growth-ready-for-u-s-move-shares-up-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418689\" data-ts=\"1545343086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418689-proteostasis-down-11-after-hours-on-delay-in-data-readout-from-early-stage-study-of-cf\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostasis down 11% after hours on delay in data readout from early-stage study of CF triplet therapy</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>) is down <font color=\"red\">11%</font> after hours on light volume following its <a href=\"https://seekingalpha.com/pr/17364980-proteostasis-therapeutics-provides-clinical-enrollment-update\" target=\"_blank\">announcement</a> that it will not report preliminary data from its Phase 1 clinical trial evaluating cystic fibrosis &#40;CF&#41; triplet therapy PTI-808/PTI-801/PTI-428 until next quarter.</li><li>The company had planned to report interim results by dose cohort. It says that it remains blinded to the data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418689\" data-linked=\"Proteostasis down 11% after hours on delay in data readout from early-stage study of CF triplet therapy\" data-tweet=\"$PTI - Proteostasis down 11% after hours on delay in data readout from early-stage study of CF triplet therapy https://seekingalpha.com/news/3418689-proteostasis-down-11-after-hours-on-delay-in-data-readout-from-early-stage-study-of-cf?source=tweet\" data-url=\"https://seekingalpha.com/news/3418689-proteostasis-down-11-after-hours-on-delay-in-data-readout-from-early-stage-study-of-cf\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418683\" data-ts=\"1545342458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418683-cheddar-no-cash-bonus-for-snap-workers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheddar: No cash bonus for Snap workers</a></h4><ul><li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) employees won't receive cash bonuses for the second year in a row, according to Cheddar sources.</li><li>Top employees will receive more stock as a discretionary incentive bonus.</li><li>Snap shares are <font color=\"green\">up 0.8%</font> after closing today <font color=\"red\">down 6.3%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418683\" data-linked=\"Cheddar: No cash bonus for Snap workers\" data-tweet=\"$SNAP - Cheddar: No cash bonus for Snap workers https://seekingalpha.com/news/3418683-cheddar-no-cash-bonus-for-snap-workers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418683-cheddar-no-cash-bonus-for-snap-workers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418675\" data-ts=\"1545341561\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418675-nikeplus-8-on-q2-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike +8% on Q2 beats</a></h4><ul><li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>)<font color=\"green\"> gains 7.8%</font> aftermarket on Q2 results that beat EPS and revenue estimates with $0.52 and $9.37B (+10% Y/Y). Guidance will come on the call.</li><li>Revenue breakdown: NIKE brand, $8.9B (+14% Y/Y in constant currency); Converse, $425M (+6% Y/Y; consensus: $414.1M).</li><li>Gross margin was 43.8% (consensus: 43.6%).</li><li>Total SG&amp;A expense was $3.14B or 33.5% of revenue (consensus: 33.9%).</li><li>Inventories were $5.39B (-1% Y/Y).</li><li>Earnings call is scheduled for 5 PM ET with a webcast available <a href=\"https://investors.nike.com/Home/default.aspx\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17364937-nike-inc-reports-fiscal-2019-second-quarter-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418661-nike-beats-0_07-beats-revenue\" target=\"_blank\">Nike beats by $0.07, beats on revenue</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418675\" data-linked=\"Nike +8% on Q2 beats\" data-tweet=\"$NKE - Nike +8% on Q2 beats https://seekingalpha.com/news/3418675-nikeplus-8-on-q2-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3418675-nikeplus-8-on-q2-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418663\" data-ts=\"1545340691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMP\" target=\"_blank\">CAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418663-calampminus-11_5-on-q3-misses-downside-revenue-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CalAmp -11.5% on Q3 misses, downside revenue guide</a></h4><ul><li>CalAmp (NASDAQ:<a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a>) <font color=\"red\">plunges 11.5%</font> aftermarket on Q3 results that missed EPS and revenue estimates with $0.25 and $88.5M (-6% Y/Y), respectively. Q4 guidance has downside revenue of $86M to $92M (consensus: $92.35M) and in-line EPS of $0.23 to $0.29 (consensus: $0.27).</li><li>Revenue breakdown: Telematics Systems, $68.6M; Software &amp; Subscription Services, $19.9M.</li><li><ul><li>Adjusted EBITDA was $11.4M (consensus: $12.0M) and gross margin was 41.1% versus the 40.8% in last year's period.</li></ul></li><li>Earnings call is scheduled for 4:30 PM EST with a webcast available <a href=\"http://www.calamp.com/\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17364889-calamp-reports-fiscal-2019-third-quarter-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418651-calamp-misses-0_03-misses-revenue\" target=\"_blank\">CalAmp misses by $0.03, misses on revenue</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418663\" data-linked=\"CalAmp -11.5% on Q3 misses, downside revenue guide\" data-tweet=\"$CAMP - CalAmp -11.5% on Q3 misses, downside revenue guide https://seekingalpha.com/news/3418663-calampminus-11_5-on-q3-misses-downside-revenue-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3418663-calampminus-11_5-on-q3-misses-downside-revenue-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418661\" data-ts=\"1545340588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418661-nike-beats-0_07-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike beats by $0.07, beats on revenue</a></h4><ul><li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>): Q2 GAAP EPS of $0.52 <span style=\"color:green\">beats by $0.07</span>.</li><li>Revenue of $9.37B (+9.6% Y/Y) <font color=\"green\">beats by $200M</font>.</li><li>Shares <font color=\"green\">+4%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17364937-nike-inc-reports-fiscal-2019-second-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418661\" data-linked=\"Nike beats by $0.07, beats on revenue\" data-tweet=\"$NKE - Nike beats by $0.07, beats on revenue https://seekingalpha.com/news/3418661-nike-beats-0_07-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3418661-nike-beats-0_07-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418655\" data-ts=\"1545340353\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZNGA\" target=\"_blank\">ZNGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418655-zynga-to-acquire-majority-stake-in-small-giant-games-for-560m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zynga to acquire majority stake in Small Giant Games for $560M</a></h4><ul><li>Zynga (NASDAQ:<a href='https://seekingalpha.com/symbol/ZNGA' title='Zynga'>ZNGA</a>) has <a href=\"https://seekingalpha.com/pr/17364888-zynga-enters-agreement-acquire-small-giant-games-creator-hit-mobile-game-franchise-empires\" target=\"_blank\">agreed to acquire</a> an 80% stake in Finnish mobile gaming shop Small Giant Games for $560M, $330M in cash plus $230M in unregistered ZNGA common stock. The transaction should close by month-end.</li><li>ZNGA also updates its 2018 guidance, including increased revenue of $243M (from $235M) and non-GAAP EBITDA of $33M (from $32M).</li><li>Management will host a conference call at 5:00 pm ET to discuss the deal.</li><li>Shares are down <font color=\"red\">3%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418655\" data-linked=\"Zynga to acquire majority stake in Small Giant Games for $560M\" data-tweet=\"$ZNGA - Zynga to acquire majority stake in Small Giant Games for $560M https://seekingalpha.com/news/3418655-zynga-to-acquire-majority-stake-in-small-giant-games-for-560m?source=tweet\" data-url=\"https://seekingalpha.com/news/3418655-zynga-to-acquire-majority-stake-in-small-giant-games-for-560m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418646\" data-ts=\"1545339915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RFIL\" target=\"_blank\">RFIL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418646-rf-industries-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RF Industries reports Q4 results</a></h4><ul><li>RF Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/RFIL' title='RF Industries, Ltd.'>RFIL</a>): Q4 Non-GAAP EPS of $0.09; GAAP EPS of $0.05.</li><li>Revenue of $9.89M (+40.7% Y/Y)</li><li>Shares <font color=\"green\">+2.02%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17364853-rf-industries-reports-q4-income-continuing-operations-0_9-million-0_09-eps-record-net-income\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418646\" data-linked=\"RF Industries reports Q4 results\" data-tweet=\"$RFIL - RF Industries reports Q4 results https://seekingalpha.com/news/3418646-rf-industries-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3418646-rf-industries-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418642\" data-ts=\"1545339412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEAM\" target=\"_blank\">TEAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418642-dealreporter-atlassian-good-acquisition-target-for-google\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dealreporter: Atlassian good acquisition target for Google</a></h4><ul><li>Dealreporter cites industry sources saying Atlassian (<a href='https://seekingalpha.com/symbol/TEAM' title='Atlassian'>TEAM</a> <font color='green'>+0.6%</font>)would be a good acquisition target for Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='red'>-1.6%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='red'>-1.4%</font>) to further its cloud strategy.</li><li>Google could step up its acquisitions after the departure of Google Cloud head Diane Greene, reportedly due to the lack of market share growth in the unit.</li><li>Source: Bloomberg First Word.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418642\" data-linked=\"Dealreporter: Atlassian good acquisition target for Google\" data-tweet=\"$TEAM $TEAM $GOOG - Dealreporter: Atlassian good acquisition target for Google https://seekingalpha.com/news/3418642-dealreporter-atlassian-good-acquisition-target-for-google?source=tweet\" data-url=\"https://seekingalpha.com/news/3418642-dealreporter-atlassian-good-acquisition-target-for-google\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418640\" data-ts=\"1545338975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418640-reuters-ibm-hpe-victims-of-chinese-hacking\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: IBM, HPE victims of Chinese hacking</a></h4><ul><li>Reuters<a href=\"https://www.reuters.com/article/us-china-cyber-hpe-ibm-exclusive/exclusive-china-hacked-hpe-ibm-and-then-attacked-clients-sources-idUSKCN1OJ2OY?feedType=RSS&amp;feedName=technologyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtechnologyNews+%28Reuters+Technology+News%29\" target=\"_blank\"> sources</a> say Chinese state-backed hackers breached IBM (<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> <font color=\"red\">-3.2%</font>) and HPE (<a href='https://seekingalpha.com/symbol/HPE' title='Hewlett Packard Enterprise'>HPE</a> <font color=\"red\">-3.6%</font>) networks. The hackers then accessed client computers.</li><li>The attacks were part of the Cloudhopper security threat warned of by cybersecurity experts and government agencies since last year.</li><li>Cloudhopper infiltrated the networks of IBM, HPE, and other unnamed companies multiple times and for weeks and months.</li><li>IBM reportedly investigated an attack as recently as this past summer while HPE conducted an investigation early last year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418577-justice-departments-accuses-china-tech-giant-hacks\" target=\"_blank\">Justice Departments accuses China of tech giant hacks</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418640\" data-linked=\"Reuters: IBM, HPE victims of Chinese hacking\" data-tweet=\"$IBM $IBM $HPE - Reuters: IBM, HPE victims of Chinese hacking https://seekingalpha.com/news/3418640-reuters-ibm-hpe-victims-of-chinese-hacking?source=tweet\" data-url=\"https://seekingalpha.com/news/3418640-reuters-ibm-hpe-victims-of-chinese-hacking\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418632\" data-ts=\"1545337138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DGLY\" target=\"_blank\">DGLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418632-digital-alley-up-24-on-axon-withdrawal-from-patent-challenge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Alley up 24% on Axon withdrawal from patent challenge</a></h4><ul><li>Thinly traded nano cap Digital Alley (<a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color=\"green\">+24.2%</font>) is up on more than double normal volume, albeit on turnover of only 328K shares, on the heels of its <a href=\"https://seekingalpha.com/pr/17363934-axon-enterprises-taser-acknowledges-validity-digital-s-auto-activation-292-patent-dismissing\" target=\"_blank\">announcement</a> that auto-activation patent challenger Axon Enterprise (<a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color=\"red\">-2.8%</font>) has abandoned its appeal of its U.S. Patent No. 8,781,292 and will discontinue further challenges to the patent's validity.</li><li>AXON was unsuccessful in four separate petitions starting over two years ago.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418632\" data-linked=\"Digital Alley up 24% on Axon withdrawal from patent challenge\" data-tweet=\"$DGLY $DGLY $AXON-OLD - Digital Alley up 24% on Axon withdrawal from patent challenge https://seekingalpha.com/news/3418632-digital-alley-up-24-on-axon-withdrawal-from-patent-challenge?source=tweet\" data-url=\"https://seekingalpha.com/news/3418632-digital-alley-up-24-on-axon-withdrawal-from-patent-challenge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418633\" data-ts=\"1545336884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418633-jpmorgan-twitter-sell-off-overdone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan: Twitter sell-off &quot;overdone&quot;</a></h4><ul><li>JPMorgan says the Twitter (NYSE:<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a>) sell-off after Citron's comments is \"overdone.\"</li><li>Analyst Douglas Anmuth: \u201cTWTR\u2019s platform health efforts will ultimately have a positive impact on engagement and advertising over time.\"</li><li>The firm reiterates its Overweight rating and $45 price target and calls Twitter one of its top picks for 2019.</li><li>Source: Bloomberg First Word.</li><li>Twitter shares are<font color=\"red\"> down 10.8%</font> to $29.36.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418536-twitter-minus-8-percent-citron-mention-20-target\" target=\"_blank\">Twitter  -8% on Citron mention, $20 target</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418633\" data-linked=\"JPMorgan: Twitter sell-off &quot;overdone&quot;\" data-tweet=\"$TWTR - JPMorgan: Twitter sell-off &quot;overdone&quot; https://seekingalpha.com/news/3418633-jpmorgan-twitter-sell-off-overdone?source=tweet\" data-url=\"https://seekingalpha.com/news/3418633-jpmorgan-twitter-sell-off-overdone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418629\" data-ts=\"1545336100\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INPX\" target=\"_blank\">INPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418629-mxwl-neon-and-run-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MXWL, NEON and RUN among tech movers</a></h4><ul><li><strong>Gainers: </strong>Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"green\">+36%</font>. Digital Ally (NASDAQ:<a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a>) <font color=\"green\">+23%</font>. Neonode (NASDAQ:<a href='https://seekingalpha.com/symbol/NEON' title='Neonode, Inc.'>NEON</a>) <font color=\"green\">+19%</font>. Zedge (NYSEMKT:<a href='https://seekingalpha.com/symbol/ZDGE' title='Zedge, Inc.'>ZDGE</a>) <font color=\"green\">+13%</font>. Maxwell Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/MXWL' title='Maxwell Technologies, Inc.'>MXWL</a>) <font color=\"green\">+13%</font>.</li> <li><strong>Losers: </strong>China TechFaith Wireless Communication Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/CNTF' title='China TechFaith Wireless Communication Technology Limited'>CNTF</a>) <font color=\"red\">-39%</font>. ChinaCache International Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a>) <font color=\"red\">-27%</font>. Sunrun (NASDAQ:<a href='https://seekingalpha.com/symbol/RUN' title='Sunrun'>RUN</a>) <font color=\"red\">-18%</font>. Interlink Electronics (NASDAQ:<a href='https://seekingalpha.com/symbol/LINK' title='Interlink Electronics'>LINK</a>) <font color=\"red\">-17%</font>. Uxin (NASDAQ:<a href='https://seekingalpha.com/symbol/UXIN' title='Uxin'>UXIN</a>) <font color=\"red\">-17%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3418629\" data-linked=\"MXWL, NEON and RUN among tech movers\" data-tweet=\"$INPX $INPX $DGLY - MXWL, NEON and RUN among tech movers https://seekingalpha.com/news/3418629-mxwl-neon-and-run-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418629-mxwl-neon-and-run-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418624\" data-ts=\"1545335045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418624-scalise-promises-wall-funding-stocks-bounce\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scalise promises Wall funding, stocks bounce</a></h4><ul><li>GOP Rep. Steve Scalise <a href=\"https://twitter.com/ryanobles/status/1075824515337412611\" target=\"_blank\">says $5B funding will be added</a> to the stopgap funding bill, seemingly paving the way for the president to sign and end the government shutdown threat.</li><li>Whether House leaders can round up the votes to pass Wall funding is another question, but the major averages have bounced about 1% from the lows in the past 30 minutes. The S&amp;P 500 is now <font color=\"red\">off 1.25%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418624\" data-linked=\"Scalise promises Wall funding, stocks bounce\" data-tweet=\"Scalise promises Wall funding, stocks bounce https://seekingalpha.com/news/3418624-scalise-promises-wall-funding-stocks-bounce?source=tweet\" data-url=\"https://seekingalpha.com/news/3418624-scalise-promises-wall-funding-stocks-bounce\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>161&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418619\" data-ts=\"1545333408\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VECO\" target=\"_blank\">VECO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418619-veecoplus-4_7-on-target-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veeco +4.7% on target boost</a></h4><ul><li>Northland Capital raises its Veeco Instruments (NASDAQ:<a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a>) price target from $11 to $14.</li><li>Analyst Gus Richard also boosts VECO's 2019 estimates on EUV equipment demand and expectations of sustained demand for advanced packaging, but LED isn't expected to improve in the near future.</li><li>Source: Bloomberg First Word.</li><li>Veeco shares are <font color=\"green\">up 4.7%</font> to $7.15.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418619\" data-linked=\"Veeco +4.7% on target boost\" data-tweet=\"$VECO - Veeco +4.7% on target boost https://seekingalpha.com/news/3418619-veecoplus-4_7-on-target-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3418619-veecoplus-4_7-on-target-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418618\" data-ts=\"1545333375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418618-oil-renews-plunge-sending-energy-sector-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil renews plunge, sending energy sector down 3%</a></h4><ul><li>The bounce in crude was pretty short-lived, with WTI <font color=\"red\">down 4.5%</font> on the session to a new roughly 15-month low of $46 per barrel. That's got the Energy SPDR <font color=\"red\">down more than 3%</font>.</li><li>The move comes alongside building panic in the stock market, with the S&amp;P 500 - still digesting the Fed's surprising hawkishness, and now worried about the renewed threat of a government shutdown - <font color=\"red\">off another 2.5%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418615-oil-slump-sends-big-investor-fleeing-blackrock-energy-etf\" target=\"_blank\">Oil slump sends big investor fleeing from BlackRock energy ETF</a> (Dec. 20)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/UGA' title='The United States Gasoline ETF, LP'>UGA</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/UHN' title='The United States Diesel-Heating Oil ETF, LP'>UHN</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/OILK' title='ProShares K-1 Free Crude Oil Strategy ETF'>OILK</a>, <a href='https://seekingalpha.com/symbol/OILX' title='Etracs S&P GSCI Crude Oil Total Return Index ETN'>OILX</a>, <a href='https://seekingalpha.com/symbol/WTID' title='ProShares Daily 3x Inverse Crude ETN'>WTID</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a>, <a href='https://seekingalpha.com/symbol/USOU' title='United States 3x Oil Fund'>USOU</a>, <a href='https://seekingalpha.com/symbol/USOD' title='United States 3x Short Oil Fund ETF'>USOD</a>, <a href='https://seekingalpha.com/symbol/OILD' title='ProShares UltraPro 3x Short Crude Oil ETF'>OILD</a>, <a href='https://seekingalpha.com/symbol/OILU' title='ProShares UltraPro 3x Crude Oil ETF'>OILU</a>, <a href='https://seekingalpha.com/symbol/USAI' title='American Energy Independence ETF'>USAI</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418618\" data-linked=\"Oil renews plunge, sending energy sector down 3%\" data-tweet=\"$USO $OIL $UWT - Oil renews plunge, sending energy sector down 3% https://seekingalpha.com/news/3418618-oil-renews-plunge-sending-energy-sector-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3418618-oil-renews-plunge-sending-energy-sector-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418616\" data-ts=\"1545333019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418616-gold-catches-modest-bid-panic-sets-in-for-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold catches modest bid as panic sets in for stocks</a></h4><ul><li>Stocks continue to reel from the Fed's surprising hawkishness yesterday, with today's renewed threat of a government shutdown adding to the excuses to sell.</li><li>In fast action, all three major averages have now <font color=\"red\">fallen more than 2%</font> on the session.</li><li>Gold is seeing something resembling a bid, <font color=\"green\">up 0.9%</font> to $1,268 per ounce, and now <font color=\"green\">higher by about 6%</font> over the past month.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='Aberdn Std Gold Shs'>SGOL</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/GTU' title='Central Gold-Trust'>GTU</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/DGL' title='Inv DB Mul-Sec Shs Invesco DB Gold Fund'>DGL</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/GYEN' title='AdvisorShares Gartman Gold/Yen ETF'>GYEN</a>, <a href='https://seekingalpha.com/symbol/BAR' title='GraniteShares Gold Trust ETF'>BAR</a>, <a href='https://seekingalpha.com/symbol/GEUR' title='AdvisorShares Gartman Gold/Euro ETF'>GEUR</a>, <a href='https://seekingalpha.com/symbol/GLDW' title='SPDR Long Dollar Gold Trust ETF'>GLDW</a>, <a href='https://seekingalpha.com/symbol/GHS' title='REX Gold Hedged S&P 500 ETF'>GHS</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/QGLDX' title='The Gold Bullion Strategy Fund Inv'>QGLDX</a>, <a href='https://seekingalpha.com/symbol/GHE' title='REX Gold Hedged FTSE Emerging Markets ETF'>GHE</a>, <a href='https://seekingalpha.com/symbol/AAAU' title='Perth Mint Physical Gold ETF'>AAAU</a>, <a href='https://seekingalpha.com/symbol/GLDM' title='World Gold Shares SPDR Gold Minishares Trust ETF'>GLDM</a>, <a href='https://seekingalpha.com/symbol/IAUF' title='iShares Gold Strategy ETF'>IAUF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418616\" data-linked=\"Gold catches modest bid as panic sets in for stocks\" data-tweet=\"$GLD $IAU $PHYS - Gold catches modest bid as panic sets in for stocks https://seekingalpha.com/news/3418616-gold-catches-modest-bid-panic-sets-in-for-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3418616-gold-catches-modest-bid-panic-sets-in-for-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418615\" data-ts=\"1545332668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418615-oil-slump-sends-big-investor-fleeing-from-blackrock-energy-etf\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil slump sends big investor fleeing from BlackRock energy ETF</a></h4><ul><li>With oil sitting near its lowest level since August 2017, at least one large investor is dumping BlackRock's iShares Global Energy ETF (<a href='https://seekingalpha.com/symbol/IXC' title='iShares Global Energy ETF'>IXC</a> <font color=\"red\">-1.9%</font>).</li><li>Two large blocks of the $1.4B ETF sold on Wednesday--one for 1.1M shares worth $34M at 10:37 AM ET, and the other a block of almost 2M shares worth $60M about eight minutes later, Bloomberg reports.</li><li>IXC's turnover for the day came to $144M, the most this month and about 10 times the daily average for the year.</li><li>Oil is <font color=\"red\">down 4.3%</font> in midafternoon trading at $46.12.</li><li>Of course, IXC isn't alone. Energy Select Sector SPDR ETF (<a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a> <font color=\"red\">-3.1%</font>), Vanguard Energy ETF (<a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a> <font color=\"red\">-3.1%</font>), VanEck Vectors Oil Services ETF (<a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a> <font color=\"red\">-3.5%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418378-energy-shares-cheapest-relatively-speaking-since-2001\" target=\"_blank\">Energy shares cheapest (relatively speaking) since 2001</a> (Dec. 19)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/RYE' title='Invesco S&P Equal Weight Energy ETF'>RYE</a>, <a href='https://seekingalpha.com/symbol/PXJ' title='Invesco Dynamic Oil & Gas Services Portfolio ETF'>PXJ</a>, <a href='https://seekingalpha.com/symbol/CRAK' title='VanEck Vectors Oil Refiners ETF'>CRAK</a>, <a href='https://seekingalpha.com/symbol/FXN' title='First Trust Energy AlphaDEX ETF'>FXN</a>, <a href='https://seekingalpha.com/symbol/DDG' title='ProShares Short Oil & Gas ETF'>DDG</a>, <a href='https://seekingalpha.com/symbol/NANR' title='SPDR S&P North American Natural Resources ETF'>NANR</a>, <a href='https://seekingalpha.com/symbol/FTXN' title='First Trust Nasdaq Oil & Gas ETF'>FTXN</a>, <a href='https://seekingalpha.com/symbol/JHME' title='John Hancock Multifactor Energy ETF'>JHME</a>, <a href='https://seekingalpha.com/symbol/ERYY' title='Direxion Daily Energy Bear 1x Shares ETF'>ERYY</a>, <a href='https://seekingalpha.com/symbol/ERGF' title='iShares Edge MSCI Multifactor Energy ETF'>ERGF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418615\" data-linked=\"Oil slump sends big investor fleeing from BlackRock energy ETF\" data-tweet=\"$IXC $XLE $VDE - Oil slump sends big investor fleeing from BlackRock energy ETF https://seekingalpha.com/news/3418615-oil-slump-sends-big-investor-fleeing-from-blackrock-energy-etf?source=tweet\" data-url=\"https://seekingalpha.com/news/3418615-oil-slump-sends-big-investor-fleeing-from-blackrock-energy-etf\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418614\" data-ts=\"1545332632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418614-one-snap-bear-rings-register\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">One Snap bear rings the register</a></h4><ul><li>BTIG's Rich Greenfield is closing out his Sell recommendation on Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>), upgrading to Neutral.</li><li>Shares are <font color=\"red\">down another 5.9%</font> today, and <font color=\"red\">66%</font> YTD.</li><li><strong>Update at 2:30 ET:</strong> More details <a href=\"https://www.marketwatch.com/story/snap-is-no-longer-a-compelling-short-says-btig-2018-12-20\" target=\"_blank\">courtesy of Marketwatch</a> ... While Greenfield still has concerns, Snap is no longer a compelling short at these levels, he says. \"To meaningfully grow revenues Snapchat needs content consumption within Discover to become far more meaningful than it is today ... We continue to believe the entire Snapchat product might need to change if Snapchat really wants to attract a wider demographic of users.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3418614\" data-linked=\"One Snap bear rings the register\" data-tweet=\"$SNAP - One Snap bear rings the register https://seekingalpha.com/news/3418614-one-snap-bear-rings-register?source=tweet\" data-url=\"https://seekingalpha.com/news/3418614-one-snap-bear-rings-register\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418613\" data-ts=\"1545332599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSM\" target=\"_blank\">FSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418613-gold-stocks-lifted-soft-dollar-hornbeck-offshore-services-and-platinum-group-among-energy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold stocks lifted by soft dollar; Hornbeck Offshore Services and Platinum Group among Energy/Materials losers</a></h4><ul><li><b>Gainers: </b>Fortuna Silver Mines (NYSE:<a href='https://seekingalpha.com/symbol/FSM' title='Fortuna Silver Mines'>FSM</a>) <font color=\"green\">+12%</font>. DRDGOLD (NYSE:<a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a>) <font color=\"green\">+11%</font>. Americas Silver (NYSEMKT:<a href='https://seekingalpha.com/symbol/USAS' title='Americas Silver Corporation'>USAS</a>) <font color=\"green\">+11%</font>. IAMGOLD (NYSE:<a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a>) <font color=\"green\">+11%</font>. Coeur Mining (NYSE:<a href='https://seekingalpha.com/symbol/CDE' title='Coeur Mining, Inc.'>CDE</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Hornbeck Offshore Services (NYSE:<a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a>) <font color=\"red\">-17%</font>. Platinum Group Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLG' title='Platinum Group Metals Ltd'>PLG</a>) <font color=\"red\">-14%</font>. Synthesis Energy Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/SES' title='Synthesis Energy Systems, Inc.'>SES</a>) <font color=\"red\">-14%</font>. Noble Corporation (NYSE:<a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a>) <font color=\"red\">-13%</font>. Oceaneering International (NYSE:<a href='https://seekingalpha.com/symbol/OII' title='Oceaneering International Inc.'>OII</a>) <font color=\"red\">-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418613\" data-linked=\"Gold stocks lifted by soft dollar; Hornbeck Offshore Services and Platinum Group among Energy/Materials losers\" data-tweet=\"$FSM $FSM $DRD - Gold stocks lifted by soft dollar; Hornbeck Offshore Services and Platinum Group among Energy/Materials losers https://seekingalpha.com/news/3418613-gold-stocks-lifted-soft-dollar-hornbeck-offshore-services-and-platinum-group-among-energy?source=tweet\" data-url=\"https://seekingalpha.com/news/3418613-gold-stocks-lifted-soft-dollar-hornbeck-offshore-services-and-platinum-group-among-energy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418608\" data-ts=\"1545331881\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPOT\" target=\"_blank\">SPOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418608-spotify-settles-1_6b-wixen-suit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spotify settles $1.6B Wixen suit</a></h4><ul><li>Spotify (NYSE:<a href='https://seekingalpha.com/symbol/SPOT' title='Spotify'>SPOT</a>) <a href=\"https://techcrunch.com/2018/12/20/spotify-settles-the-1-6b-copyright-lawsuit-filed-by-music-publisher-wixen/\" target=\"_blank\">settles</a> the $1.6B Wixen Music Publishing lawsuit filed last year alleging the streaming service was using tens of thousands of songs without a proper license.</li><li>Financial terms weren't disclosed, but Spotify hasn't filed a disclosure with the SEC suggesting a lower amount. Sources tell TechCrunch that all of the settlement is going to back royalty payments and the agreement involves a new payment structure.</li><li>Wixen artists included Tom Petty, Stevie Nicks, and Neil Young.</li><li>Spotify shares are <font color=\"red\">down 4.3%</font> to $113.66.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418608\" data-linked=\"Spotify settles $1.6B Wixen suit\" data-tweet=\"$SPOT - Spotify settles $1.6B Wixen suit https://seekingalpha.com/news/3418608-spotify-settles-1_6b-wixen-suit?source=tweet\" data-url=\"https://seekingalpha.com/news/3418608-spotify-settles-1_6b-wixen-suit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418592\" data-ts=\"1545329322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDE\" target=\"_blank\">CDE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418592-gold-miners-rise-precious-metals-set-for-best-quarter-in-almost-two-years\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold miners rise, as precious metals set for best quarter in almost two years</a></h4><ul><li>As investors flee the volatile stock markets and the dollar weakens, gold rises; Comex February gold <font color=\"green\">+0.7%</font> to $1,265.70/oz.</li><li>For most of the year, it's been a bad run for gold, but precious metals are set for their <a href=\"https://www.marketwatch.com/story/golds-down-for-the-year-but-set-to-shine-in-2019-2018-12-20?dist=markets\" target=\"_blank\">biggest quarterly gain </a>in almost two years, analysts say.</li><li>VanEck Vectors Gold Miners ETF (<a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a> <font color='green'>+4.2%</font>) up 2.6% over the past three months, -18% YTD.</li><li>Many precious metals miners are on the rise: (<a href='https://seekingalpha.com/symbol/CDE' title='Coeur Mining, Inc.'>CDE</a> <font color='green'>+8.7%</font>),  (<a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='green'>+4.7%</font>), (<a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a> <font color='green'>+6.9%</font>), (<a href='https://seekingalpha.com/symbol/AUY' title='Yamana Gold Inc.'>AUY</a> <font color='green'>+6.7%</font>), (<a href='https://seekingalpha.com/symbol/HL' title='Hecla Mining Co.'>HL</a> <font color='green'>+3.4%</font>), (<a href='https://seekingalpha.com/symbol/BVN' title='Compañía de Minas Buenaventura S.A.A.'>BVN</a> <font color='green'>+5.2%</font>), (<a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color='green'>+8%</font>), (<a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a> <font color='green'>+6.7%</font>), (<a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a> <font color='green'>+6.8%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399800-gold-miners-rise-gold-price-hits-three-month-high\" target=\"_blank\">Gold miners rise as gold price hits three-month high</a> (Oct. 23)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a>, <a href='https://seekingalpha.com/symbol/NUGT' title='Direxion Daily Gold Miners Index Bull 3x Shares ETF'>NUGT</a>, <a href='https://seekingalpha.com/symbol/GGN' title='GAMCO Global Gold, Natural Resources & Income Trust'>GGN</a>, <a href='https://seekingalpha.com/symbol/DUST' title='Direxion Daily Gold Miners Index Bear 3x Shares ETF'>DUST</a>, <a href='https://seekingalpha.com/symbol/GOEX' title='Global X Gold Explorers ETF'>GOEX</a>, <a href='https://seekingalpha.com/symbol/SGDM' title='Sprott Gold Miners ETF'>SGDM</a>, <a href='https://seekingalpha.com/symbol/ASA' title='ASA Gold&Precious Metals'>ASA</a>, <a href='https://seekingalpha.com/symbol/RING' title='iShares MSCI Global Gold Miners ETF'>RING</a>, <a href='https://seekingalpha.com/symbol/TGLDX' title='Tocqueville Gold Fund No Load'>TGLDX</a>, <a href='https://seekingalpha.com/symbol/PSAU' title='Invesco Global Gold and Precious Metals Portfolio ETF'>PSAU</a>, <a href='https://seekingalpha.com/symbol/GOAU' title='U.S. Global GO GOLD and Precious Metal Miners ETF'>GOAU</a>, <a href='https://seekingalpha.com/symbol/GDXX' title='ProShares Ultra Gold Miners ETF'>GDXX</a>, <a href='https://seekingalpha.com/symbol/GDXS' title='ProShares UltraShort Gold Miners ETF'>GDXS</a>, <a href='https://seekingalpha.com/symbol/MELT' title='Direxion Daily Gold Miners Index Bear 1x Shares ETF'>MELT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418592\" data-linked=\"Gold miners rise, as precious metals set for best quarter in almost two years\" data-tweet=\"$CDE $GDX $CDE - Gold miners rise, as precious metals set for best quarter in almost two years https://seekingalpha.com/news/3418592-gold-miners-rise-precious-metals-set-for-best-quarter-in-almost-two-years?source=tweet\" data-url=\"https://seekingalpha.com/news/3418592-gold-miners-rise-precious-metals-set-for-best-quarter-in-almost-two-years\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418590\" data-ts=\"1545328603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YRIV\" target=\"_blank\">YRIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418590-ehealth-and-triple-s-management-among-financial-gainers-china-internet-nationwide-financial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">eHealth and Triple-S Management among financial gainers; China Internet Nationwide Financial Services leads losers</a></h4><ul><li><b>Gainers: </b>Yangtze River Port and Logistics (NASDAQ:<a href='https://seekingalpha.com/symbol/YRIV' title='Yangtze River Port and Logistics Limited'>YRIV</a>) <font color=\"green\">+10%</font>. eHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/EHTH' title='eHealth, Inc.'>EHTH</a>) <font color=\"green\">+6%</font>. Triple-S Management (NYSE:<a href='https://seekingalpha.com/symbol/GTS' title='Triple-S Management Corporation'>GTS</a>) <font color=\"green\">+6%.</font></li><li><b>Losers: </b>China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"red\">-17%</font>. Medley Management (NYSE:<a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management'>MDLY</a>) <font color=\"red\">-14%</font>. Wheeler Real Estate Investment Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a>) <font color=\"red\">-11%</font>. Focus Financial Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/FOCS' title='Focus Financial Partners'>FOCS</a>) <font color=\"red\">-9%</font>. Elbit Imaging (NASDAQ:<a href='https://seekingalpha.com/symbol/EMITF' title='Elbit Imaging Ltd.'>EMITF</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418590\" data-linked=\"eHealth and Triple-S Management among financial gainers; China Internet Nationwide Financial Services leads losers\" data-tweet=\"$YRIV $YRIV $EHTH - eHealth and Triple-S Management among financial gainers; China Internet Nationwide Financial Services leads losers https://seekingalpha.com/news/3418590-ehealth-and-triple-s-management-among-financial-gainers-china-internet-nationwide-financial?source=tweet\" data-url=\"https://seekingalpha.com/news/3418590-ehealth-and-triple-s-management-among-financial-gainers-china-internet-nationwide-financial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418589\" data-ts=\"1545328299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418589-quebec-to-cover-biogens-sma-med-spinraza\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Quebec to cover Biogen&#39;s SMA med Spinraza</a></h4><ul><li>Health authorities in the Canadian province of Quebec have decided to cover Biogen's (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"green\">+0.8%</font>) SPINRAZA (nusinersen) for the treatment of a broad population of patients with spinal muscular atrophy &#40;SMA&#41;.</li><li>Predictably, the company <a href=\"https://seekingalpha.com/pr/17364599-biogen-applauds-quebec-decision-cover-spinraza-nusinersen-broad-population-sma-patients\" target=\"_blank\">applauds </a>the decision.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418589\" data-linked=\"Quebec to cover Biogen&#39;s SMA med Spinraza\" data-tweet=\"$BIIB - Quebec to cover Biogen&#39;s SMA med Spinraza https://seekingalpha.com/news/3418589-quebec-to-cover-biogens-sma-med-spinraza?source=tweet\" data-url=\"https://seekingalpha.com/news/3418589-quebec-to-cover-biogens-sma-med-spinraza\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418588\" data-ts=\"1545327603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INPX\" target=\"_blank\">INPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418588-healthcare-tech-dominate-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare &amp; Tech dominate midday movers</a></h4><ul><li><strong>Gainers: </strong>Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"green\">+37%</font>. Agenus (NASDAQ:<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a>) <font color=\"green\">+28%</font>. Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a>) <font color=\"green\">+18%</font>. Vaxart (NASDAQ:<a href='https://seekingalpha.com/symbol/VXRT' title='Vaxart, Inc.'>VXRT</a>) <font color=\"green\">+16%</font>. Digital Ally (NASDAQ:<a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a>) <font color=\"green\">+16%</font>. Neonode (NASDAQ:<a href='https://seekingalpha.com/symbol/NEON' title='Neonode, Inc.'>NEON</a>) <font color=\"green\">+15%</font>. Fennec Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/FENC' title='Fennec Pharmaceuticals, Inc.'>FENC</a>) <font color=\"green\">+15%</font>. NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/NFEC' title='NF Energy Saving Corp.'>NFEC</a>) <font color=\"green\">+14%</font>. Aimmune Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics'>AIMT</a>) <font color=\"green\">+13%</font>. Kezar Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/KZR' title='Kezar Life Sciences'>KZR</a>) <font color=\"green\">+12%</font>.</li> <li><strong>Losers: </strong>DBV Technologies S.A. (NASDAQ:<a href='https://seekingalpha.com/symbol/DBVT' title='DBV Technologies'>DBVT</a>) <font color=\"red\">-71%</font>. ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics Inc'>ADMA</a>) <font color=\"red\">-48%</font>. Pier 1 Imports (NYSE:<a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a>) <font color=\"red\">-43%</font>. G1 Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GTHX' title='G1 Therapeutics'>GTHX</a>) <font color=\"red\">-39%</font>. Spectrum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a>) <font color=\"red\">-37%</font>. MannKind Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) <font color=\"red\">-34%</font>. China TechFaith Wireless Communication Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/CNTF' title='China TechFaith Wireless Communication Technology Limited'>CNTF</a>) <font color=\"red\">-32%</font>. PLx Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PLXP' title='PLx Pharma'>PLXP</a>) <font color=\"red\">-28%</font>. ChinaCache International Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a>) <font color=\"red\">-25%</font>. Naked Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a>) <font color=\"red\">-24%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3418588\" data-linked=\"Healthcare &amp; Tech dominate midday movers\" data-tweet=\"$INPX $INPX $AGEN - Healthcare &amp; Tech dominate midday movers https://seekingalpha.com/news/3418588-healthcare-tech-dominate-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418588-healthcare-tech-dominate-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418583\" data-ts=\"1545326631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEE\" target=\"_blank\">NEE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418583-utilities-back-to-fading-s-and-ps-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Utilities back to fading the S&amp;P&#39;s decline</a></h4><ul><li>Somewhat disturbing about this week's selloff in stocks and resulting decline in long-term rates was that it left no sector untouched - not even the highly defensive utilities, which would seemingly benefit from the sharp drop in long-dated yields.</li><li>That concern may be easing a little today, as the <a href='https://seekingalpha.com/symbol/XLU' title='Utilities Select Sector SPDR ETF'>XLU</a> <font color=\"green\">gains 0.7%</font> alongside the S&amp;P 500's <font color=\"red\">1.25% decline</font>.</li><li>Next Era (<a href='https://seekingalpha.com/symbol/NEE' title='NextEra Energy, Inc.'>NEE</a> <font color='green'>+0.6%</font>), Duke (<a href='https://seekingalpha.com/symbol/DUK' title='Duke Energy Corporation'>DUK</a> <font color='green'>+1.7%</font>), Dominion (<a href='https://seekingalpha.com/symbol/D' title='Dominion Energy, Inc.'>D</a> <font color='green'>+1.7%</font>), Southern Company (<a href='https://seekingalpha.com/symbol/SO' title='Southern Company'>SO</a> <font color='green'>+0.5%</font>), PPL (<a href='https://seekingalpha.com/symbol/PPL' title='PPL Corporation'>PPL</a> <font color='green'>+1.9%</font>), WEC Energy (<a href='https://seekingalpha.com/symbol/WEC' title='WEC Energy Group, Inc.'>WEC</a> <font color='green'>+1.4%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLU' title='Utilities Select Sector SPDR ETF'>XLU</a>, <a href='https://seekingalpha.com/symbol/UTG' title='Reaves Utility Income Fund'>UTG</a>, <a href='https://seekingalpha.com/symbol/VPU' title='Vanguard Utilities ETF'>VPU</a>, <a href='https://seekingalpha.com/symbol/GUT' title='Gabelli Utility Trust'>GUT</a>, <a href='https://seekingalpha.com/symbol/IDU' title='iShares U.S. Utilities ETF'>IDU</a>, <a href='https://seekingalpha.com/symbol/BUI' title='BlackRock Utility&Infrastructure Trust'>BUI</a>, <a href='https://seekingalpha.com/symbol/FUTY' title='Fidelity MSCI Utilities Index ETF'>FUTY</a>, <a href='https://seekingalpha.com/symbol/RYU' title='Invesco S&P Equal Weight Utilities ETF'>RYU</a>, <a href='https://seekingalpha.com/symbol/UPW' title='ProShares Ultra Utilities ETF'>UPW</a>, <a href='https://seekingalpha.com/symbol/FXU' title='First Trust Utilities AlphaDEX ETF'>FXU</a>, <a href='https://seekingalpha.com/symbol/SDP' title='ProShares UltraShort Utilities ETF'>SDP</a>, <a href='https://seekingalpha.com/symbol/FUGAX' title='Fidelity Advisor® Utilities Fund A'>FUGAX</a>, <a href='https://seekingalpha.com/symbol/JHMU' title='John Hancock Multifactor Utilities ETF'>JHMU</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418583\" data-linked=\"Utilities back to fading the S&amp;P&#39;s decline\" data-tweet=\"$NEE $XLU $NEE - Utilities back to fading the S&amp;P&#39;s decline https://seekingalpha.com/news/3418583-utilities-back-to-fading-s-and-ps-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/3418583-utilities-back-to-fading-s-and-ps-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418579\" data-ts=\"1545325409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REVG\" target=\"_blank\">REVG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418579-earnings-related-stocks-revg-nakd-and-cvgw-among-consumer-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Earnings related stocks REVG, NAKD and CVGW among consumer losers</a></h4><ul><li><b>Losers: </b>REV Group (NYSE:<a href='https://seekingalpha.com/symbol/REVG' title='REV Group'>REVG</a>) <font color=\"red\">-23%</font>. Greif (NYSE:<a href='https://seekingalpha.com/symbol/GEF' title='Greif, Inc.'>GEF</a>) <font color=\"red\">-16%</font>. Naked Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a>) <font color=\"red\">-15%</font>. China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"red\">-12%</font>. Calavo Growers (NASDAQ:<a href='https://seekingalpha.com/symbol/CVGW' title='Calavo Growers, Inc.'>CVGW</a>) <font color=\"red\">-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418579\" data-linked=\"Earnings related stocks REVG, NAKD and CVGW among consumer losers\" data-tweet=\"$REVG $REVG $GEF - Earnings related stocks REVG, NAKD and CVGW among consumer losers https://seekingalpha.com/news/3418579-earnings-related-stocks-revg-nakd-and-cvgw-among-consumer-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418579-earnings-related-stocks-revg-nakd-and-cvgw-among-consumer-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418577\" data-ts=\"1545325154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418577-justice-departments-accuses-china-of-tech-giant-hacks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Justice Departments accuses China of tech giant hacks</a></h4><ul><li>The U.S. Justice Department <a href=\"https://techcrunch.com/2018/12/20/us-indictment-tech-hacks-chinese/?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\">unseals an indictment</a> linking the Chinese government to an aggressive hacking campaign targeting U.S. tech giants.</li><li>Prosecutors allege the hackers hit dozens of tech companies and government departments largely in a bid to steal IP.</li><li>Company names weren't provided but the targets spanned aviation, satellite tech, pharmaceutical, oil and gas exploration, and computer processor firms, to name a few.</li><li>The indictment also says the hackers stole personal data on over 100K U.S. Navy personnel. The data included names, Social Security numbers, dates of birth, and email addresses.</li><li>U.S. deputy attorney general Rod Rosenstein: \u201cWe want China to cease illegal cyber activities and honor its commitment to the international community, but the evidence suggests that China may not intend to live up to its promises.\u201d</li><li>Read the indictment <a href=\"http://www.documentcloud.org/documents/5638865-US-vs-Zhu-Hua-Indictment.html\" target=\"_blank\">here</a>.</li><li>Related cybersecurity ETFs: <a href='https://seekingalpha.com/symbol/HACK' title='PureFunds ISE Cyber Security ETF'>HACK</a>, <a href='https://seekingalpha.com/symbol/CIBR' title='First Trust Nasdaq CEA Cybersecurity ETF'>CIBR</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418577\" data-linked=\"Justice Departments accuses China of tech giant hacks\" data-tweet=\"$HACK $CIBR - Justice Departments accuses China of tech giant hacks https://seekingalpha.com/news/3418577-justice-departments-accuses-china-of-tech-giant-hacks?source=tweet\" data-url=\"https://seekingalpha.com/news/3418577-justice-departments-accuses-china-of-tech-giant-hacks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418571\" data-ts=\"1545324317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBIO\" target=\"_blank\">MBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418571-mustang-bios-mbminus-102-orphan-drug-in-u-s-for-rare-type-of-blood-cancer-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mustang Bio&#39;s MB-102 an Orphan Drug in U.S. for rare type of blood cancer; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17364089-mustang-bio-receives-orphan-drug-designation-mbminus-102-cd123-car-t-treatment-blastic\" target=\"_blank\">designates </a>Mustang Bio's (<a href='https://seekingalpha.com/symbol/MBIO' title='Mustang Bio, Inc.'>MBIO</a> <font color=\"green\">+0.8%</font>) CAR-T candidate MB-102 an Orphan Drug for the treatment of blastic plasmacytoid dendritic cell neoplasm &#40;BPDCN&#41;, a rare and incurable blood cancer with a median survival of less than 18 months with no effective treatment options.</li><li>MB-102 is currently in Phase 1 development for treatment-resistant AML.</li><li>Among the benefits of Orphan Drug status in the U.S. is a seven-year period for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418571\" data-linked=\"Mustang Bio&#39;s MB-102 an Orphan Drug in U.S. for rare type of blood cancer; shares up 1%\" data-tweet=\"$MBIO - Mustang Bio&#39;s MB-102 an Orphan Drug in U.S. for rare type of blood cancer; shares up 1% https://seekingalpha.com/news/3418571-mustang-bios-mbminus-102-orphan-drug-in-u-s-for-rare-type-of-blood-cancer-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3418571-mustang-bios-mbminus-102-orphan-drug-in-u-s-for-rare-type-of-blood-cancer-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418567\" data-ts=\"1545323802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XERS\" target=\"_blank\">XERS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418567-xeris-pharmas-liquid-glucagon-orphan-drug-is-europe-for-rare-insulin-disorder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xeris Pharma&#39;s liquid glucagon an Orphan Drug is Europe for rare insulin disorder</a></h4><ul><li>The European Medicines Agency <a href=\"https://seekingalpha.com/pr/17364061-european-medicines-agency-grants-orphan-drug-designation-xeris-investigational-ready-use\" target=\"_blank\">designates </a>Xeris Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/XERS' title='Xeris Pharmaceuticals'>XERS</a> <font color=\"red\">-15.2%</font>) ready-to-use liquid glucagon for the treatment of <a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome\" target=\"_blank\">noninsulinoma pancreatogenous hypoglycemia syndrome</a> &#40;NIPHS&#41;, a rare metabolic disorder characterized by elevated levels of insulin in the blood and low blood glucose.</li><li>Post-gastric bypass hypoglycemia (low blood sugar) presents similar features but it considered a separate clinical entity.</li><li>Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418567\" data-linked=\"Xeris Pharma&#39;s liquid glucagon an Orphan Drug is Europe for rare insulin disorder\" data-tweet=\"$XERS - Xeris Pharma&#39;s liquid glucagon an Orphan Drug is Europe for rare insulin disorder https://seekingalpha.com/news/3418567-xeris-pharmas-liquid-glucagon-orphan-drug-is-europe-for-rare-insulin-disorder?source=tweet\" data-url=\"https://seekingalpha.com/news/3418567-xeris-pharmas-liquid-glucagon-orphan-drug-is-europe-for-rare-insulin-disorder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418561\" data-ts=\"1545322873\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418561-netflixminus-2_4-bull-cuts-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix -2.4% as Bull cuts target</a></h4><ul><li>Buckingham Research cuts its Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) target from $406 to $382 citing the S&amp;P 500 sell-off.</li><li>Analyst Matthew Harrigan sticks with a Buy rating as he still sees Netflix as the \"top global streaming category winner\" and is constructive on the company's pricing power beyond global member growth.</li><li>Source: Bloomberg First Word.</li><li>Netflix shares are<font color=\"red\"> down 2.4%</font> to $260.28.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418561\" data-linked=\"Netflix -2.4% as Bull cuts target\" data-tweet=\"$NFLX - Netflix -2.4% as Bull cuts target https://seekingalpha.com/news/3418561-netflixminus-2_4-bull-cuts-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3418561-netflixminus-2_4-bull-cuts-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418557\" data-ts=\"1545321980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAFM\" target=\"_blank\">SAFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418557-sanderson-farms-rises-after-q4-sales-exceed-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanderson Farms rises after Q4 sales exceed consensus</a></h4><ul><li>Sanderson Farms (NASDAQ:<a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a>)<font color=\"green\"> jumps 7.3% </font>after Q4 net sales of $798.1M beat the consensus estimate of $783M.</li><li>Stock move likely from comments made during <a href=\"http://ir.sandersonfarms.com/events-and-presentations\" target=\"_blank\">conference call</a>.</li><li>Compared with a year ago, net sales fell 13% from $919.9M, reflecting weaker market conditions and two hurricanes that affected operations in North Carolina and Georgia.</li></ul><ul><li>With no debt at fiscal year-end, \"we believe our balance sheet provides us with the financial strength not only to support our growth strategy, but also to consistently manage our operations through the cycles that characterize our industry,\" says Chairman and CEO Joe F. Sanderson, Jr.</li><li>Overall realized prices for poultry products were 9.2% lower in FY2018 vs. last year, and were significantly lower in Q4, the company said.</li><li>Q4 boneless breast meat prices fell 26% Y/Y on average.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418439-sanderson-farms-misses-0_28-beats-revenue\" target=\"_blank\">Sanderson Farms misses by $0.28, beats on revenue</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418557\" data-linked=\"Sanderson Farms rises after Q4 sales exceed consensus\" data-tweet=\"$SAFM - Sanderson Farms rises after Q4 sales exceed consensus https://seekingalpha.com/news/3418557-sanderson-farms-rises-after-q4-sales-exceed-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3418557-sanderson-farms-rises-after-q4-sales-exceed-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418555\" data-ts=\"1545321879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGEN\" target=\"_blank\">AGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418555-agenus-leads-healthcare-gainers-mannkind-and-spectrum-pharmaceuticals-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agenus leads healthcare gainers; MannKind and Spectrum Pharmaceuticals among losers</a></h4><ul><li><b>Gainers: </b>Agenus (NASDAQ:<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a>) <font color=\"green\">+43%</font>. Aimmune Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics'>AIMT</a>) <font color=\"green\">+15%</font>. Fennec Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/FENC' title='Fennec Pharmaceuticals, Inc.'>FENC</a>) <font color=\"green\">+15%</font>. FibroGen (NASDAQ:<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a>) <font color=\"green\">+12%</font>. PolarityTE (NASDAQ:<a href='https://seekingalpha.com/symbol/PTE' title='PolarityTE, Inc.'>PTE</a>) <font color=\"green\">+12%</font>.</li><li><b>Losers: </b>DBV Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/DBVT' title='DBV Technologies'>DBVT</a>) <font color=\"red\">-68%</font>. ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics Inc'>ADMA</a>) <font color=\"red\">-44%</font>. Spectrum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a>) <font color=\"red\">-33%</font>. MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) <font color=\"red\">-32%</font>. G1 Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GTHX' title='G1 Therapeutics'>GTHX</a>) <font color=\"red\">-29%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418555\" data-linked=\"Agenus leads healthcare gainers; MannKind and Spectrum Pharmaceuticals among losers\" data-tweet=\"$AGEN $AGEN $AIMT - Agenus leads healthcare gainers; MannKind and Spectrum Pharmaceuticals among losers https://seekingalpha.com/news/3418555-agenus-leads-healthcare-gainers-mannkind-and-spectrum-pharmaceuticals-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418555-agenus-leads-healthcare-gainers-mannkind-and-spectrum-pharmaceuticals-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418551\" data-ts=\"1545321450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EB\" target=\"_blank\">EB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418551-eventbriteminus-10-on-stifel-move-to-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eventbrite -10% on Stifel move to sidelines</a></h4><ul><li>Stifel downgrades Eventbrite (NYSE:<a href='https://seekingalpha.com/symbol/EB' title='Eventbrite'>EB</a>) from Buy to Hold citing a \"more balanced\" risk-reward profile and the fact that the stock is trading at the higher end of its peers.</li><li>Analyst Scott Devitt remains confident in the company's leadership position and long-term market opportunity but sees limited near-term upsides in valuation and the March 19 lockup period expiration.</li><li>Source: Bloomberg First Word.</li><li>EB shares are <font color=\"red\">down 10.4%</font> to $29.51.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418551\" data-linked=\"Eventbrite -10% on Stifel move to sidelines\" data-tweet=\"$EB - Eventbrite -10% on Stifel move to sidelines https://seekingalpha.com/news/3418551-eventbriteminus-10-on-stifel-move-to-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3418551-eventbriteminus-10-on-stifel-move-to-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418548\" data-ts=\"1545321272\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REVG\" target=\"_blank\">REVG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418548-rev-group-slips-19-after-disappointing-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">REV Group slips 19% after disappointing Q4 results</a></h4><ul><li>REV Group (<a href='https://seekingalpha.com/symbol/REVG' title='REV Group'>REVG</a> <font color=\"red\">-19.5%</font>) reported Q4 net sales decrease of 3.5% Y/Y to $659.8M, due to lower Fire &amp; Emergency segment shipments.</li><li>Sale by segments: Fire &amp; Emergency $250.5M (-21.1% Y/Y); Commercial $181.9M (+3.4% Y/Y) and Recreation $235.4M (+24.6% Y/Y).</li><li>Q4 Gross profit <font color=\"red\">declined by 300 bps</font> to 11.1% and operating margin <font color=\"red\">declined by 881 bps </font>to -2.8%.</li><li>Adj. EBITDA decreased 32.5% Y/Y to $39.4M and margin <font color=\"red\">declined by 260 bps</font> to 6%.</li><li>Net cash used in by operating activities YTD was $19.2M, as compared to cash provided $33.2M a year ago.</li><li>Company has Cash and cash equivalents of $11.9M, as of October 31, 2018; and Total backlog was 1.38B (+25.3% Y/Y).</li><li>Company announced it sold its mobility van business, Revability, with annual sales of ~$40M, on December 19, 2018.</li><li><strong>FY19 outlook: </strong>Net sales of $2.4-2.6B; Net income of $43-63M; Adj Net Income of $66-84M; Adj. EBITDA<sup> </sup>of $150-170M; Capex $25-30M and net cash provided by operating activities of $110-130M.</li><li>\u201cWe are disappointed with our financial results for fiscal year 2018. Fiscal 2018 was a year in which we were confronted with the strong headwinds from the impacts of tariffs, chassis availability, material lead time extensions and temporary labor inefficiencies,\u201d commented Tim ­Sullivan, CEO.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418356-rev-group-misses-0_24-misses-revenue\" target=\"_blank\">REV Group misses by $0.24, misses on revenue</a> (Dec. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418357-rev-group-declares-0_05-dividend\" target=\"_blank\">REV Group declares $0.05 dividend</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418548\" data-linked=\"REV Group slips 19% after disappointing Q4 results\" data-tweet=\"$REVG - REV Group slips 19% after disappointing Q4 results https://seekingalpha.com/news/3418548-rev-group-slips-19-after-disappointing-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3418548-rev-group-slips-19-after-disappointing-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418547\" data-ts=\"1545320616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARDM\" target=\"_blank\">ARDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418547-third-party-verification-of-aradigms-late-stage-studies-of-inhalable-ciprofloxacin-completed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Third party verification of Aradigm&#39;s late-stage studies of inhalable ciprofloxacin completed; shares up 2%</a></h4><ul><li>Aradigm (<a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color=\"green\">+2.1%</font>) <a href=\"https://seekingalpha.com/pr/17363911-aradigm-announces-results-third-party-verification-apulmiq-formerly-linhaliq\" target=\"_blank\">announces </a>the completion of the third-party evaluation of its Phase 3 ORBIT-3 and ORBIT-4 studies evaluating Apulmiq (formerly Linhaliq) (ciprofloxacin for inhalation) for the treatment for non-cystic fibrosis bronchiectasis patients with chronic lung infection with <em>Pseudomonas aeruginosa</em> (<em>P. aeruginosa</em>). The FDA requested the re-evaluation in its CRL issued in January.</li><li>The company says the independent evaluation verified the results from both trials. It plans to meet with the agency to discuss the data.</li><li>Concurrently, it has received a letter from the FDA regarding its on-site inspection in January confirming no violations or deficiencies.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3325954-fda-rejects-aradigms-marketing-application-linhaliq-ncfbe\" target=\"_blank\">FDA rejects Aradigm's marketing application for Linhaliq for NCFBE</a> (Jan. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418547\" data-linked=\"Third party verification of Aradigm&#39;s late-stage studies of inhalable ciprofloxacin completed; shares up 2%\" data-tweet=\"$ARDM - Third party verification of Aradigm&#39;s late-stage studies of inhalable ciprofloxacin completed; shares up 2% https://seekingalpha.com/news/3418547-third-party-verification-of-aradigms-late-stage-studies-of-inhalable-ciprofloxacin-completed?source=tweet\" data-url=\"https://seekingalpha.com/news/3418547-third-party-verification-of-aradigms-late-stage-studies-of-inhalable-ciprofloxacin-completed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418544\" data-ts=\"1545320162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418544-cruise-ships-slide-on-carnival-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cruise ships slide on Carnival outlook</a></h4><ul><li>Cruise ship stocks fell the pressure from this morning's Carnival (<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a> <font color='red'>-7.2%</font>) report, which beat Q4 revenue and EPS estimates but included downside Q1 EPS guide at $0.40 to $0.44 (consensus: $0.45) and in-line FY at $4.50 to $4.80 (consensus: $4.69).</li><li>Earnings <a href=\"https://seekingalpha.com/pr/17364322-carnival-corporation-and-plc-reports-fourth-quarter-record-full-year-earnings\" target=\"_blank\">press release</a>.</li><li>On the move: (<a href='https://seekingalpha.com/symbol/RCL' title='Royal Caribbean Cruises Ltd.'>RCL</a> <font color='red'>-2.9%</font>), (<a href='https://seekingalpha.com/symbol/NCLH' title='Norwegian Cruise Line Holdings Ltd.'>NCLH</a> <font color='red'>-3.5%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418500-carnival-beats-0_01-beats-revenue\" target=\"_blank\">Carnival beats by $0.01, beats on revenue</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418544\" data-linked=\"Cruise ships slide on Carnival outlook\" data-tweet=\"$CCL $CCL $RCL - Cruise ships slide on Carnival outlook https://seekingalpha.com/news/3418544-cruise-ships-slide-on-carnival-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3418544-cruise-ships-slide-on-carnival-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418543\" data-ts=\"1545319845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418543-natural-gas-inventory-draw-was-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory draw was more than expected</a></h4><ul><li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory:</a> <strong>-141 Bcf</strong> vs. -132 Bcf consensus, -77 Bcf last week.</li><li>Futures <font color=\"green\">+1.91%</font> to $3.797.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a> en</li></ul><div class=\"tiny-share-widget\" data-id=\"3418543\" data-linked=\"Natural gas inventory draw was more than expected\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory draw was more than expected https://seekingalpha.com/news/3418543-natural-gas-inventory-draw-was-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3418543-natural-gas-inventory-draw-was-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418542\" data-ts=\"1545319742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418542-conagra-sinks-11-after-light-fy2019-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ConAgra sinks 11% after light FY2019 guidance</a></h4><ul><li>ConAgra (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a>) <font color=\"red\">slumps 11%</font> after<a href=\"https://seekingalpha.com/pr/17363848-conagra-brands-reports-second-quarter-results\" target=\"_blank\"> FY2019 guidance</a> for adjusted EPS from continuing operations falls short of the consensus estimate.</li><li>Sees total FY2019 adjusted EPS from continuing operations of $2.03-$2.08; consensus estimate of $2.12.</li><li>Sees total ConAgra reported net sales up 22%-23% for the year; organic net sales, excluding Trenton, up 1.0%-2.0%.</li><li>Reaffirms FY2019 net sales, margin guidance for legacy ConAgra brands.</li><li>Fiscal Q2 organic net sales, excluding the sale of its Trenton, MO, plant, slid 1.6%; 220 basis points of decline in organic sales growth attributed to the impact of hurricanes in the prior-year period.</li><li>Q2 net sales for grocery &amp; snacks segment basically flat at $900M; organic net sales declined 1.9%.</li><li>Q2 refrigerated &amp; frozen segment net sales increased 1.7% to $722M; organic net sales +0.5%.</li><li>Sees exceeding $215M Pinnacle-related cost synergy target.</li><li>\"While this work will take time, we have done this before and remain confident in our ability to enhance Pinnacle's portfolio of leading brands and drive long-term shareholder value,\" says ConAgra President and CEO Sean Connolly.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418438-conagra-brands-beats-0_10-beats-revenue\" target=\"_blank\">ConAgra Brands beats by $0.10, beats on revenue</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418542\" data-linked=\"ConAgra sinks 11% after light FY2019 guidance\" data-tweet=\"$CAG - ConAgra sinks 11% after light FY2019 guidance https://seekingalpha.com/news/3418542-conagra-sinks-11-after-light-fy2019-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3418542-conagra-sinks-11-after-light-fy2019-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418536\" data-ts=\"1545319290\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418536-twitterminus-8-on-citron-mention-20-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter  -8% on Citron mention, $20 target</a></h4><ul><li>Twitter (NYSE:<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a>) <font color=\"red\">plunges 8.4% </font>after Citron Research <a href=\"https://twitter.com/CitronResearch/status/1075765949108707328\" target=\"_blank\">says </a>an Amnesty International report shouldn't be ignored by investors and the company \"will be forced to clean up the site,\" leading to swift MAU impact.</li><li>Citron also calls TWTR the \"Harvey Weinstein of social media.\"</li><li>Citron puts a $20 price target on the company.</li><li>Read more <a href=\"https://www.amnesty.org/en/latest/news/2018/12/crowdsourced-twitter-study-reveals-shocking-scale-of-online-abuse-against-women/\" target=\"_blank\">here</a> about the Amnesty International report on \"shocking\" online abuse against women on Twitter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418536\" data-linked=\"Twitter  -8% on Citron mention, $20 target\" data-tweet=\"$TWTR - Twitter -8% on Citron mention, $20 target https://seekingalpha.com/news/3418536-twitterminus-8-on-citron-mention-20-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3418536-twitterminus-8-on-citron-mention-20-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>67&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418535\" data-ts=\"1545318682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418535-ibm-taps-samsung-for-7nm-processes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM taps Samsung for 7nm processes</a></h4><ul><li>IBM (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>) expands its strategic partnership with Samsung to include manufacturing 7nm processes.</li><li>Samsung will manufacture microprocessors for IBM Power Systems, IBM Z and LinuxONE, high-performance computing systems, and cloud offerings.</li><li>IBM was using GlobalFoundries for its process technologies, but GlobalFoundries announced earlier this year it would put its 7nm FinFET program on hold indefinitely. Samsung and TSMC (NYSE:<a href='https://seekingalpha.com/symbol/TSM' title='Taiwan Semiconductor Manufacturing Company Ltd.'>TSM</a>) are the remaining 7nm players.</li><li>The agreement expands and extends the 15-year strategic process tech R&amp;D partnership between the companies.</li><li>IBM shares are <font color=\"red\">down 0.9%</font> to $115.49.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418535\" data-linked=\"IBM taps Samsung for 7nm processes\" data-tweet=\"$IBM $IBM $TSM - IBM taps Samsung for 7nm processes https://seekingalpha.com/news/3418535-ibm-taps-samsung-for-7nm-processes?source=tweet\" data-url=\"https://seekingalpha.com/news/3418535-ibm-taps-samsung-for-7nm-processes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418528\" data-ts=\"1545318251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BDRAF\" target=\"_blank\">BDRAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418528-bombardier-gets-contracts-for-18-trams-20-locomotives\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bombardier gets contracts for 18 trams, 20 locomotives</a></h4><ul><li>Bombardier (<a href='https://seekingalpha.com/symbol/BDRAF' title='Bombardier Inc.A'>OTCQX:BDRAF</a> <font color='green'>+1.4%</font>) gets two contracts valued at up to $192M in total based on list prices.</li><li>Wiener Lokalbahnen <a href=\"https://seekingalpha.com/pr/17363750-bombardier-wins-contract-supply-maintain-18-flexity-trams-wiener-lokalbahnen\" target=\"_blank\">signs contract</a> for 18 FLEXITY trams, including maintenance management system over 24 years; contract, including option for 16 more vehicles and eight more years of servicing and maintenance, valued at about 94M euros ($107M).</li><li>Railpool, a rail vehicle leasing company in Europe, orders 20 electric <a href=\"https://seekingalpha.com/pr/17364279-bombardier-receives-orders-provide-20-traxx-locomotives-railpool\" target=\"_blank\">TRAXX locomotives</a>; contract, including options for up to 20 additional vehicles, valued at 74M euros ($85M).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417401-bombardier-supply-flexity-trams-karlsruhe\" target=\"_blank\">Bombardier to supply FLEXITY trams to Karlsruhe</a> (Dec. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418528\" data-linked=\"Bombardier gets contracts for 18 trams, 20 locomotives\" data-tweet=\"$BDRAF - Bombardier gets contracts for 18 trams, 20 locomotives https://seekingalpha.com/news/3418528-bombardier-gets-contracts-for-18-trams-20-locomotives?source=tweet\" data-url=\"https://seekingalpha.com/news/3418528-bombardier-gets-contracts-for-18-trams-20-locomotives\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418517\" data-ts=\"1545317415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADSK\" target=\"_blank\">ADSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418517-autodesk-pays-275m-for-construction-platform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Autodesk pays $275M for construction platform</a></h4><ul><li>Autodesk (NASDAQ:<a href='https://seekingalpha.com/symbol/ADSK' title='Autodesk, Inc.'>ADSK</a>) <a href=\"https://seekingalpha.com/pr/17364285-autodesk-acquire-buildingconnected-leading-construction-bid-management-platform\" target=\"_blank\">acquires</a> construction bid-management platform BuildingConnected for $275M net of cash. The deal is expected to close in Q4 FY19 and will have no material impact on the Q4 or FY19 guidance.</li><li>In FY20, ADSK expects immaterial revenue and ARR benefits from the acquisition and slightly dilutive impacts to profitability and cash flow.</li><li>The acquisition adds bid management, risk analysis and other preconstruction solutions to Autodesk's construction portfolio.</li><li>BuildingConnected's network has more than 700K construction professionals and helps real estate owners and general contractors find and hire contractors. Customers include Turner Construction, McCarthy, Mortenson, StructureTone, Skanska, Clark Construction, Ryan Companies, and AECOM.</li><li>In other acquisition news, Autodesk <a href=\"https://seekingalpha.com/pr/17364256-autodesk-completes-plangrid-acquisition\" target=\"_blank\">completes</a> its $875M PlanGrid purchase.</li><li>Autodesk shares are<font color=\"red\"> down 0.6%</font> to $127.35.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418517\" data-linked=\"Autodesk pays $275M for construction platform\" data-tweet=\"$ADSK - Autodesk pays $275M for construction platform https://seekingalpha.com/news/3418517-autodesk-pays-275m-for-construction-platform?source=tweet\" data-url=\"https://seekingalpha.com/news/3418517-autodesk-pays-275m-for-construction-platform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418514\" data-ts=\"1545316857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMU\" target=\"_blank\">IMMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418514-immunomedics-down-21-ahead-of-bearish-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immunomedics down 21% ahead of bearish report</a></h4><ul><li>Immunomedics (<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color=\"red\">-20.8%</font>) is down on average volume in apparent anticipation of a bearish report from <a href=\"http://www.favusinstitutionalresearch.com/\" target=\"_blank\">Favus Researc</a>h.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418514\" data-linked=\"Immunomedics down 21% ahead of bearish report\" data-tweet=\"$IMMU - Immunomedics down 21% ahead of bearish report https://seekingalpha.com/news/3418514-immunomedics-down-21-ahead-of-bearish-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3418514-immunomedics-down-21-ahead-of-bearish-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418507\" data-ts=\"1545316140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAOV\" target=\"_blank\">NAOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418507-nanovibronix-signs-major-distributor-in-india-for-uroshield\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NanoVibronix signs major distributor in India for UroShield</a></h4><ul> <li>NanoVibronix (NASDAQ:<a href='https://seekingalpha.com/symbol/NAOV' title='NanoVibronix, Inc.'>NAOV</a>) in <a href=\"https://seekingalpha.com/pr/17363932-nanovibronix-signs-major-distributor-india-uroshield\" target=\"_blank\">partnership</a> with Morulaa HealthTech has signed a new distribution agreement for UroShield with Cnergy Group of Companies.</li>   <li>UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections.</li>  <li>Financial details are not disclosed.</li><li>Shares are up <font color=\"green\">16%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3418507\" data-linked=\"NanoVibronix signs major distributor in India for UroShield\" data-tweet=\"$NAOV - NanoVibronix signs major distributor in India for UroShield https://seekingalpha.com/news/3418507-nanovibronix-signs-major-distributor-in-india-for-uroshield?source=tweet\" data-url=\"https://seekingalpha.com/news/3418507-nanovibronix-signs-major-distributor-in-india-for-uroshield\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418503\" data-ts=\"1545315813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGEN\" target=\"_blank\">AGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418503-tlry-agen-and-au-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TLRY, AGEN and AU among premarket gainers</a></h4><ul><li>Agenus (NASDAQ:<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a>) <font color=\"green\">+51%</font> on <a href=\"https://seekingalpha.com/news/3418445-agenus-teams-gilead-develop-five-o-therapies-shares-72-percent-premarket\" target=\"_blank\">collaborating</a> with Gilead Sciences to develop five immuno-oncology (I-O) therapies.</li><li>LM Funding America (NASDAQ:<a href='https://seekingalpha.com/symbol/LMFA' title='LM Funding America, Inc.'>LMFA</a>) <font color=\"green\">+21%</font> after <a href=\"https://seekingalpha.com/pr/17364004-lm-funding-signs-letter-intent-acquire-global-medical-insurance-product-company-iiu-inc\" target=\"_blank\">signing</a> LOI to acquire Global Medical Insurance Product Company.</li><li>Aimmune Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics'>AIMT</a>) <font color=\"green\">+13%</font> on <a href=\"https://seekingalpha.com/pr/17363955-aimmune-therapeutics-announces-ind-filing-ar201-egg-allergy-exclusive-supply-agreement\" target=\"_blank\">announcing</a> IND filing for AR201 for egg allergy.</li><li>Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"green\">+9%</font>.</li><li>Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) <font color=\"green\">+11%</font>.</li><li>Tenax Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TENX' title='Tenax Therapeutics, Inc.'>TENX</a>) <font color=\"green\">+8%</font>.</li><li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <font color=\"green\">+7%</font> on Street-high <a href=\"https://seekingalpha.com/news/3418455-pareteum-plus-9_5-percent-street-high-target\" target=\"_blank\">target</a>.</li><li>Gold Fields (NYSE:<a href='https://seekingalpha.com/symbol/GFI' title='Gold Fields Limited'>GFI</a>) <font color=\"green\">+7%</font>.</li><li>AngloGold Ashanti (NYSE:<a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a>) <font color=\"green\">+7%</font>.</li><li>Sibanye Gold (NYSE:<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a>) <font color=\"green\">+7%</font>.</li><li>Harmony Gold Mining Company (NYSE:<a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a>) <font color=\"green\">+7%</font>.</li><li>Companhia Energetica de Minas Gerais (NYSE:<a href='https://seekingalpha.com/symbol/CIG' title='Companhia Energtica de Minas Gerais - CEMIG'>CIG</a>) <font color=\"green\">+7%</font>.</li><li>GOL Linhas Aereas Inteligentes (NYSE:<a href='https://seekingalpha.com/symbol/GOL' title='GOL Linhas Aéreas Inteligentes S.A.'>GOL</a>) <font color=\"green\">+6%</font>.</li><li>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+6%</font>.</li><li>Bilibili (NASDAQ:<a href='https://seekingalpha.com/symbol/BILI' title='Bilibili'>BILI</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3418459-bilibili-plus-5-percent-alibaba-tie\" target=\"_blank\">Alibaba</a> tie-up.</li><li>IAMGOLD (NYSE:<a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a>) <font color=\"green\">+5%</font>.</li><li>First Majestic Silver (NYSE:<a href='https://seekingalpha.com/symbol/AG' title='First Majestic Silver Corp.'>AG</a>) <font color=\"green\">+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3418503\" data-linked=\"TLRY, AGEN and AU among premarket gainers\" data-tweet=\"$AGEN $AGEN $LMFA - TLRY, AGEN and AU among premarket gainers https://seekingalpha.com/news/3418503-tlry-agen-and-au-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418503-tlry-agen-and-au-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418498\" data-ts=\"1545315117\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBVT\" target=\"_blank\">DBVT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418498-healthcare-stocks-down-in-premarket-trade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare stocks down in premarket trade</a></h4><ul><li>DBV Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/DBVT' title='DBV Technologies'>DBVT</a>) <font color=\"red\">-63%</font> on <a href=\"https://seekingalpha.com/news/3418484-dbv-tech-62-percent-premarket-withdrawal-u-s-marketing-application-viaskin-peanut\" target=\"_blank\">withdrawal</a> of U.S. marketing application for Viaskin Peanut.</li><li>ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics Inc'>ADMA</a>) <font color=\"red\">-39%</font> after FDA <a href=\"https://seekingalpha.com/news/3418457-fda-rejects-adma-bios-bivigam-application-shares-42-percent-premarket\" target=\"_blank\">rejects</a> Bivigam application.</li><li>Spectrum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a>) <font color=\"red\">-35%</font> after FDA <a href=\"https://seekingalpha.com/news/3418335-fda-declines-accelerated-review-status-spectrums-poziotinib-certain-lung-cancer-patients\" target=\"_blank\">declines</a> accelerated review status for poziotinib.</li><li>MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) <font color=\"red\">-21%</font> on <a href=\"https://seekingalpha.com/news/3418412-mannkind-prices-40m-equity-offering\" target=\"_blank\">pricing</a> equity offering.</li><li>Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a>) <font color=\"red\">-10%</font>.</li><li>Immunomedics (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a>) <font color=\"red\">-8%</font>.</li><li>Motus GI Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MOTS' title='Motus GI Holdings'>MOTS</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3418413-motus-gi-announces-13_5m-follow-offering\" target=\"_blank\">announcing</a> $13.5M follow-on offering.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3418498\" data-linked=\"Healthcare stocks down in premarket trade\" data-tweet=\"$DBVT $DBVT $ADMA - Healthcare stocks down in premarket trade https://seekingalpha.com/news/3418498-healthcare-stocks-down-in-premarket-trade?source=tweet\" data-url=\"https://seekingalpha.com/news/3418498-healthcare-stocks-down-in-premarket-trade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418494\" data-ts=\"1545314633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418494-ec-oks-astrazenecas-bevespi-aerosphere-for-copd-shares-up-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EC OK&#39;s AstraZeneca&#39;s Bevespi Aerosphere for COPD; shares up 3% premarket</a></h4><ul><li>The European Commission <a href=\"https://www.astrazeneca.com/media-centre/press-releases/2018/bevespi-aerosphere-approved-in-the-eu-for-chronic-obstructive-pulmonary-disease-20122018.html\" target=\"_blank\">approves </a>AstraZeneca's (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurized metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease &#40;COPD&#41;.</li><li>The product was previously approved in the U.S., Canada, Australia, Turkey and Taiwan.</li><li>Shares are up <font color=\"green\">3%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418494\" data-linked=\"EC OK&#39;s AstraZeneca&#39;s Bevespi Aerosphere for COPD; shares up 3% premarket\" data-tweet=\"$AZN - EC OK&#39;s AstraZeneca&#39;s Bevespi Aerosphere for COPD; shares up 3% premarket https://seekingalpha.com/news/3418494-ec-oks-astrazenecas-bevespi-aerosphere-for-copd-shares-up-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3418494-ec-oks-astrazenecas-bevespi-aerosphere-for-copd-shares-up-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418484\" data-ts=\"1545314168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBVT\" target=\"_blank\">DBVT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418484-dbv-tech-down-62-premarket-on-withdrawal-of-u-s-marketing-application-for-viaskin-peanut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DBV Tech down 62% premarket on withdrawal of U.S. marketing application for Viaskin Peanut</a></h4><ul><li>Thinly traded DBV Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/DBVT' title='DBV Technologies'>DBVT</a>) is down <font color=\"red\">62% </font>premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17363476-dbv-technologies-dbv-technologies-provides-update-viaskin-peanut-children-four-11-years-age\" target=\"_blank\">voluntary withdrawal</a> of its U.S. marketing application for Viaskin Peanut for the treatment of peanut allergy in children ages 4-11.</li><li>The company says the issue relates to insufficient data on manufacturing procedures and quality control. It plans to refile the application as soon as possible.</li><li>Peanut allergy competitor Aimmune Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics'>AIMT</a>) is up <font color=\"green\">12%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418484\" data-linked=\"DBV Tech down 62% premarket on withdrawal of U.S. marketing application for Viaskin Peanut\" data-tweet=\"$DBVT $DBVT $AIMT - DBV Tech down 62% premarket on withdrawal of U.S. marketing application for Viaskin Peanut https://seekingalpha.com/news/3418484-dbv-tech-down-62-premarket-on-withdrawal-of-u-s-marketing-application-for-viaskin-peanut?source=tweet\" data-url=\"https://seekingalpha.com/news/3418484-dbv-tech-down-62-premarket-on-withdrawal-of-u-s-marketing-application-for-viaskin-peanut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418483\" data-ts=\"1545314149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418483-apple-faces-iphone-ban-in-germany-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple faces iPhone ban in Germany (update)</a></h4><ul><li>A German court <a href=\"https://www.reuters.com/article/us-apple-qualcomm-court/german-court-rules-apple-infringed-qualcomm-patent-idUSKCN1OJ1RJ?feedType=RSS&amp;feedName=technologyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtechnologyNews+%28Reuters+Technology+News%29\" target=\"_blank\">rules</a> that Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) infringed on a Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) hardware patent and the company can no longer sell certain iPhones in the country.</li><li>The ruling won't go into immediate effect if Apple appeals.</li><li>Apple shares are <font color=\"red\">down 0.5%</font> premarket while Qualcomm <font color=\"green\">gains 1.5%</font>.</li><li>Update: Apple announces it will pull iPhone 7 and iPhone 8 models from its 15 German retail locations will appealing the court decision. The iPhone XS, XS Max, and XR will remain available.</li><li>The German judge ruled that phones containing a chip from Qorvo (<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a> <font color='green'>+1%</font>) violated a Qualcomm patent related to envelope tracking, a feature that helps conserve battery power while sending and receiving wireless signals.</li><li>Qualcomm will have to post a $765M bond before beginning proceedings to enforce the court's order.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418483\" data-linked=\"Apple faces iPhone ban in Germany (update)\" data-tweet=\"$AAPL $AAPL $QCOM - Apple faces iPhone ban in Germany (update) https://seekingalpha.com/news/3418483-apple-faces-iphone-ban-in-germany-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3418483-apple-faces-iphone-ban-in-germany-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>283&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418477\" data-ts=\"1545313229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EADSY\" target=\"_blank\">EADSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418477-airbus-sheds-5-u-s-reportedly-joins-bribery-probe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airbus sheds 5% as U.S. reportedly joins bribery probe</a></h4><ul><li><a href=\"https://www.reuters.com/article/us-airbus-probe/airbus-shares-fall-after-report-of-u-s-joining-corruption-probe-idUSKCN1OJ1I0\" target=\"_blank\"><em>Le Monde</em> reports</a> the U.S. has joined France and the U.K. in the corruption probe at Airbus (<a href='https://seekingalpha.com/symbol/EADSY' title='Airbus SE ADR'>OTCPK:EADSY</a>, <a href='https://seekingalpha.com/symbol/EADSF' title='Airbus SE'>OTCPK:EADSF</a>). Fines could reach several billion euros, according to the paper.</li><li>Airbus emails Bloomberg, saying it can't comment on the proceedings, but notes it's already disclosed that U.S. investigators have requested information related to the U.K./French probe.</li><li>Shares are <font color=\"red\">down 5.1%</font> in Paris action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418477\" data-linked=\"Airbus sheds 5% as U.S. reportedly joins bribery probe\" data-tweet=\"$EADSY $EADSY $EADSF - Airbus sheds 5% as U.S. reportedly joins bribery probe https://seekingalpha.com/news/3418477-airbus-sheds-5-u-s-reportedly-joins-bribery-probe?source=tweet\" data-url=\"https://seekingalpha.com/news/3418477-airbus-sheds-5-u-s-reportedly-joins-bribery-probe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418468\" data-ts=\"1545312461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418468-ft-whatsapp-bans-130k-accounts-in-10-days\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FT: WhatsApp bans 130K accounts in 10 days</a></h4><ul><li>Facebook's (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) WhatsApp has banned 130K user accounts in the past 10 days for sharing illegal material related to child sex abuse, according to <a href=\"https://www.ft.com/content/bff119b8-0424-11e9-99df-6183d3002ee1\" target=\"_blank\">Financial Times</a>.</li><li>WhatsApp has a total user base of about 1.5B.</li><li>Sources say videos and pictures showing abuse are shared \"on a vast scale\" and WhatsApp isn't curbing the problems despite mass bans.</li><li>In September, Israeli researchers warned Facebook it was easy to find and join groups sharing that type of content. FT found several of the identified groups were still active this week.</li><li>WhatsApp's end-to-end encryption means the company (and law enforcement) can't see the content of messages, which makes it harder to check for illegal material.</li><li>WhatsApp says it \u201chas a zero-tolerance policy around child sexual abuse.\u201d</li><li>Facebook shares are <font color=\"red\">down 0.9%</font> premarket to $132.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418468\" data-linked=\"FT: WhatsApp bans 130K accounts in 10 days\" data-tweet=\"$FB - FT: WhatsApp bans 130K accounts in 10 days https://seekingalpha.com/news/3418468-ft-whatsapp-bans-130k-accounts-in-10-days?source=tweet\" data-url=\"https://seekingalpha.com/news/3418468-ft-whatsapp-bans-130k-accounts-in-10-days\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418467\" data-ts=\"1545312396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACST\" target=\"_blank\">ACST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418467-acasti-pharma-hits-enrollment-targets-in-late-stage-studies-of-capre-shares-ahead-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acasti Pharma hits enrollment targets in late-stage studies of CaPre; shares ahead 3% premarket</a></h4><ul><li>Nano cap Acasti Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma, Inc.'>ACST</a>) is up <font color=\"green\">3%</font> premarket on light volume following the <a href=\"https://seekingalpha.com/pr/17363909-acasti-pharma-achieves-planned-enrollment-targets-trilogy-phase-3-trials-capre-patients\" target=\"_blank\">full enrollment</a> of over 1,450 patients in its TRILOGY Phase 3 clinical trials evaluating CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia.</li><li>As of yesterday, more than 60% of the required total of 500 subjects from the two studies have been randomized. Topline data should be available by late 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418467\" data-linked=\"Acasti Pharma hits enrollment targets in late-stage studies of CaPre; shares ahead 3% premarket\" data-tweet=\"$ACST - Acasti Pharma hits enrollment targets in late-stage studies of CaPre; shares ahead 3% premarket https://seekingalpha.com/news/3418467-acasti-pharma-hits-enrollment-targets-in-late-stage-studies-of-capre-shares-ahead-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3418467-acasti-pharma-hits-enrollment-targets-in-late-stage-studies-of-capre-shares-ahead-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418466\" data-ts=\"1545312298\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APHA\" target=\"_blank\">APHA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418466-aphria-signs-loi-cannava-to-expand-strategic-argentinian-operations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aphria signs LOI with CANNAVA to expand strategic Argentinian operations</a></h4><ul> <li>Aphria (NYSE:<a href='https://seekingalpha.com/symbol/APHA' title='Aphria Inc.'>APHA</a>) has <a href=\"https://seekingalpha.com/pr/17363753-aphria-signs-loi-cannava-expand-strategic-argentinian-operations-province-jujuy\" target=\"_blank\">signed</a> a Letter of Intent (\"LOI\") with the Argentinian state-owned Cannabis Avatãra Sociedad del Estado (\"CANNAVA\") to enter into a cooperation agreement regarding the cultivation of cannabis that will expand the Company's strategic Argentinian operations into the Province of Jujuy.</li>                  <li>Under the terms of the agreement, ABP is to establish a facility for the cultivation, processing and manufacturing of cannabis, as well as cannabis derivative products, including cannabis oil. We understand through CANNAVA, Jujuy will produce curative oils and medicines using cannabis sativa.</li> <li>Financial terms are not disclosed.</li><li>Shares are up <font color=\"green\">4%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3418466\" data-linked=\"Aphria signs LOI with CANNAVA to expand strategic Argentinian operations\" data-tweet=\"$APHA - Aphria signs LOI with CANNAVA to expand strategic Argentinian operations https://seekingalpha.com/news/3418466-aphria-signs-loi-cannava-to-expand-strategic-argentinian-operations?source=tweet\" data-url=\"https://seekingalpha.com/news/3418466-aphria-signs-loi-cannava-to-expand-strategic-argentinian-operations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418465\" data-ts=\"1545312108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERJ\" target=\"_blank\">ERJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418465-embraerplus-2_2-after-republic-firms-order-for-100-jets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Embraer +2.2% after Republic firms order for 100 jets</a></h4><ul><li>Embraer (NYSE:<a href='https://seekingalpha.com/symbol/ERJ' title='Embraer S.A.'>ERJ</a>) ri<font color=\"green\">ses 2.2%</font> in premarket trading after Republic Airways (<a href='https://seekingalpha.com/symbol/RJETQ' title='Republic Airways Holdings, Inc.'>OTCPK:RJETQ</a>) <a href=\"https://seekingalpha.com/pr/17363771-embraer-republic-airways-firm-order-100-e175s\" target=\"_blank\">firms up </a>a contract for 100 E175 jets valued at $4.7B based on current list prices.</li><li>The firm order will be included in Embraer's Q4 2018 backlog; deliveries will start in 2020.</li><li>Contract also includes purchase rights for an additional 100 E175s with conversion rights to the E175-E2. If all purchase rights are exercised, deal's list price is $9.38B.</li><li>Agreement originally announced as a Letter of Intent at Farnborough Airshow in July.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418094-embraer-plus-2_0-percent-firm-order-azul-21-jets\" target=\"_blank\">Embraer +2.0% after firm order from Azul for 21 jets</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418465\" data-linked=\"Embraer +2.2% after Republic firms order for 100 jets\" data-tweet=\"$ERJ $ERJ $RJETQ - Embraer +2.2% after Republic firms order for 100 jets https://seekingalpha.com/news/3418465-embraerplus-2_2-after-republic-firms-order-for-100-jets?source=tweet\" data-url=\"https://seekingalpha.com/news/3418465-embraerplus-2_2-after-republic-firms-order-for-100-jets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418464\" data-ts=\"1545312038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBRV\" target=\"_blank\">NBRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418464-nabriva-therapeutics-submits-nda-for-intravenous-and-oral-lefamulin-to-treat-cabp-in-adults\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nabriva Therapeutics submits NDA for intravenous and oral lefamulin to treat CABP in adults; shares up 24% premarket</a></h4><ul> <li>Nabriva Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a>) <a href=\"https://seekingalpha.com/pr/17363831-nabriva-therapeutics-submits-new-drug-applications-u-s-food-drug-administration-intravenous\" target=\"_blank\">announces</a> the submission of two NDAs to the FDA for the oral and intravenous formulations of lefamulin, a semi-synthetic pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia &#40;CABP&#41;.</li><li>Both formulations of lefamulin were granted Qualified Infectious Disease Product and Fast Track designation by the FDA, enabling potential Priority Review of the NDAs. Nabriva Therapeutics plans to submit a marketing authorization application for lefamulin in Europe in Q1 2019.</li><li>Shares are up <font color=\"green\">24%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3418464\" data-linked=\"Nabriva Therapeutics submits NDA for intravenous and oral lefamulin to treat CABP in adults; shares up 24% premarket\" data-tweet=\"$NBRV - Nabriva Therapeutics submits NDA for intravenous and oral lefamulin to treat CABP in adults; shares up 24% premarket https://seekingalpha.com/news/3418464-nabriva-therapeutics-submits-nda-for-intravenous-and-oral-lefamulin-to-treat-cabp-in-adults?source=tweet\" data-url=\"https://seekingalpha.com/news/3418464-nabriva-therapeutics-submits-nda-for-intravenous-and-oral-lefamulin-to-treat-cabp-in-adults\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418459\" data-ts=\"1545311559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABA\" target=\"_blank\">BABA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418459-bilibiliplus-5-on-alibaba-tie-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bilibili +5% on Alibaba tie-up</a></h4><ul><li>Bilibili (NASDAQ:<a href='https://seekingalpha.com/symbol/BILI' title='Bilibili'>BILI</a>) <font color=\"green\">gains 5.2%</font> premarket after <a href=\"https://seekingalpha.com/pr/17363584-bilibili-taobao-announce-business-collaboration-e-commerce\" target=\"_blank\">announcing</a> a collaboration with Alibaba's (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>) Taobao mobile e-commerce marketplace.</li><li>BILI and Taobao will develop an ecosystem that better connects content creators, merchandise, and users on both platforms.</li><li>BILI content creators will register and operate accounts on Taobao and promote merchandise by producing creative, interactive content.</li><li>The duo will work to promote and commercialize BILI's IP and Taobao will provide its partner with technical support.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418459\" data-linked=\"Bilibili +5% on Alibaba tie-up\" data-tweet=\"$BABA $BILI $BABA - Bilibili +5% on Alibaba tie-up https://seekingalpha.com/news/3418459-bilibiliplus-5-on-alibaba-tie-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3418459-bilibiliplus-5-on-alibaba-tie-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418457\" data-ts=\"1545311539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMA\" target=\"_blank\">ADMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418457-fda-rejects-adma-bios-bivigam-application-shares-down-42-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects ADMA Bio&#39;s Bivigam application; shares down 42% premarket</a></h4><ul><li>Thinly traded micro cap ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics Inc'>ADMA</a>) is down <font color=\"red\">42% </font>premarket on light volume following its <a href=\"https://seekingalpha.com/pr/17363547-adma-biologics-provides-regulatory-update-bivigam-pas-submissions\" target=\"_blank\">announcement </a>that it received a Complete Response Letter &#40;CRL&#41; from the FDA regarding its marketing application seeking approval to relaunch BIVIGAM (intravenous immune globulin [human], 10%).</li><li>The CRL cited chemistry, manufacturing and controls &#40;CMC&#41; data. It did not request additional information on compliance status, safety, efficacy or any further info on third party contract manufacturers or vendors.</li><li>The company plans to meet promptly with the agency to address the issues.</li><li>Management will host a <a href=\"https://seekingalpha.com/pr/17363742-adma-host-conference-call-discuss-recent-regulatory-update-bivigam-pas-submissions\" target=\"_blank\">conference call</a> at 9:00 am ET to discuss the situation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418457\" data-linked=\"FDA rejects ADMA Bio&#39;s Bivigam application; shares down 42% premarket\" data-tweet=\"$ADMA - FDA rejects ADMA Bio&#39;s Bivigam application; shares down 42% premarket https://seekingalpha.com/news/3418457-fda-rejects-adma-bios-bivigam-application-shares-down-42-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3418457-fda-rejects-adma-bios-bivigam-application-shares-down-42-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418455\" data-ts=\"1545311013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418455-pareteumplus-9_5-on-street-high-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +9.5% on Street-high target</a></h4><ul><li>Northland initiates Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) at Outperform with a Street-high target of $7.50.</li><li>The firm cites TEUM's \"best-in-class Rule of 40 metric,\" which adds pro forma organic SaaS growth to EBITDA margin and totals 69 for the company.</li><li>Source: Bloomberg First Word.</li><li>Pareteum shares are <font color=\"green\">up 9.5%</font> premarket to $1.61.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418455\" data-linked=\"Pareteum +9.5% on Street-high target\" data-tweet=\"$TEUM - Pareteum +9.5% on Street-high target https://seekingalpha.com/news/3418455-pareteumplus-9_5-on-street-high-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3418455-pareteumplus-9_5-on-street-high-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418451\" data-ts=\"1545310860\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XON\" target=\"_blank\">XON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418451-intrexon-up-8-premarket-on-car-t-deal-merck-kgaa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrexon up 8% premarket on CAR-T deal with Merck KGaA</a></h4><ul><li>Intrexon (NASDAQ:<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a>) is up <font color=\"green\">8% </font>premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17363852-intrexon-merck-kgaa-darmstadt-germany-announce-agreement-realizing-precigens-vision-full\" target=\"_blank\">agreement </a>with Merck KGaA (<a href='https://seekingalpha.com/symbol/MKGAY' title='Merck KGaA ADR'>OTCPK:MKGAY</a>) to transition all development of CAR-T therapies to XON subsidiary Precigen in exchange for $150M in XON stock and a $25M convertible note with an option to receive either Precigen or XON stock.</li><li>Merck KGaA and Intrexon began collaborating in CAR-T development in 2015.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418451\" data-linked=\"Intrexon up 8% premarket on CAR-T deal with Merck KGaA\" data-tweet=\"$XON $XON $MKGAY - Intrexon up 8% premarket on CAR-T deal with Merck KGaA https://seekingalpha.com/news/3418451-intrexon-up-8-premarket-on-car-t-deal-merck-kgaa?source=tweet\" data-url=\"https://seekingalpha.com/news/3418451-intrexon-up-8-premarket-on-car-t-deal-merck-kgaa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418448\" data-ts=\"1545310560\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZUO\" target=\"_blank\">ZUO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418448-needham-calls-zuora-top-pick-for-2019-zuoplus-2_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham calls Zuora top pick for 2019; ZUO +2.3%</a></h4><ul><li>Needham upgrades Zuora (NYSE:<a href='https://seekingalpha.com/symbol/ZUO' title='Zuora, Inc.'>ZUO</a>) from Buy to Strong Buy with a $27 target. The firm calls ZUO a \"top pick for 2019.\"</li><li>Analyst Scott Berg cites a combination of \"end-market growth, strong competitive positioning, conservative estimates, and valuation\" that create an attractive entry point.</li><li>Source: Bloomberg First Word.</li><li>Zuora shares are <font color=\"green\">up 2.3%</font> premarket to $17.92.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418448\" data-linked=\"Needham calls Zuora top pick for 2019; ZUO +2.3%\" data-tweet=\"$ZUO - Needham calls Zuora top pick for 2019; ZUO +2.3% https://seekingalpha.com/news/3418448-needham-calls-zuora-top-pick-for-2019-zuoplus-2_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3418448-needham-calls-zuora-top-pick-for-2019-zuoplus-2_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418445\" data-ts=\"1545310173\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGEN\" target=\"_blank\">AGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418445-agenus-teams-up-gilead-to-develop-five-i-o-therapies-shares-up-72-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agenus teams up with Gilead to develop five I-O therapies; shares up 72% premarket</a></h4><ul><li>Agenus (NASDAQ:<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a>) is up <font color=\"green\">72%</font> premarket in reaction to its <a href=\"https://seekingalpha.com/pr/17363859-gilead-agenus-enter-collaboration-develop-immuno-oncology-therapies\" target=\"_blank\">collaboration </a>with Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) to develop five immuno-oncology (I-O) therapies.</li><li>Under the terms of the agreement, AGEN will receive $150M upfront, a $30M equity investment from GILD and up to $1.7B in milestones. GILD will receive global rights to AGEN1423 (IND to be filed by month-end) and an exclusive option to license AGEN1223 and AGEN2373 (IND filed for the former and IND on tap for H1 2019 for the latter). AGEN has the right to share in development and commercialization in the U.S. GILD will have the right of first negotiation for two additional preclinical programs.</li><li>GILD is up <font color=\"green\">1%</font> premarket.</li><li><strong>Update</strong>: On January 24, AGEN <a href=\"https://seekingalpha.com/pr/17390255-agenus-closes-150-million-immuno-oncology-transaction-gilead\" target=\"_blank\">announced </a>that the deal closed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418445\" data-linked=\"Agenus teams up with Gilead to develop five I-O therapies; shares up 72% premarket\" data-tweet=\"$AGEN $AGEN $GILD - Agenus teams up with Gilead to develop five I-O therapies; shares up 72% premarket https://seekingalpha.com/news/3418445-agenus-teams-up-gilead-to-develop-five-i-o-therapies-shares-up-72-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3418445-agenus-teams-up-gilead-to-develop-five-i-o-therapies-shares-up-72-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418444\" data-ts=\"1545310094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KEM\" target=\"_blank\">KEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418444-kemet-ceo-resigns-after-investigation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KEMET CEO resigns after investigation</a></h4><ul><li>KEMET (NYSE:<a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a>) CEO Per-Olof Loof <a href=\"https://seekingalpha.com/pr/17363865-kemet-announces-leadership-transition\" target=\"_blank\">resigns</a> after an investigation into a consensual personal relationship with an employee that was found to violate the company's policies.</li><li>EVP and CFO William Lowe will step into the CEO role, effective immediately.</li><li>Lowe had planned to step out of the CFO position on May 31 with Gregory Thompson tapped as his successor. The CEO shift bumps up Thompson's appointment to now.</li><li>KEMET shares were halted ahead of the news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418444\" data-linked=\"KEMET CEO resigns after investigation\" data-tweet=\"$KEM - KEMET CEO resigns after investigation https://seekingalpha.com/news/3418444-kemet-ceo-resigns-after-investigation?source=tweet\" data-url=\"https://seekingalpha.com/news/3418444-kemet-ceo-resigns-after-investigation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418442\" data-ts=\"1545310010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBA\" target=\"_blank\">WBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418442-walgreens-bootsminus-2_4-after-q1-report-new-cost-savings-program-launched\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Walgreens Boots -2.4% after Q1 report, new cost-savings program launched</a></h4><ul><li>Walgreens Boots Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>) <font color=\"red\">slips 1.5%</font> in premarket trading after <a href=\"https://seekingalpha.com/pr/17363810-walgreens-boots-alliance-reports-fiscal-2019-first-quarter-results\" target=\"_blank\">Q1 adjusted EPS</a> beats consensus, FY2019 outlook reaffirmed, and new cost management program targeting annual cost savings of over $1B by the end of the third year announced.</li><li>Sees significant restructuring and special charges related to the new cost-management plan; recognizes pretax charge of $30M in Q1 primarily related to retail businesses in Chile and Mexico.</li><li>Retail Pharmacy USA comparable pharmacy sales rose 2.8%; comparable retail sales fell 3.2%.</li><li>Retail Pharmacy International: U.K. comparable pharmacy sales fell 3.5% and comparable retail sales fell 2.6%.</li><li>Pharmacy wholesale sales slipped 0.2% to $5.7B, including negative currency impact of 6.8%.</li><li><a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Finvestor.walgreensbootsalliance.com&amp;esheet=51917235&amp;newsitemid=20181220005169&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestor.walgreensbootsalliance.com&amp;index=1&amp;md5=6e0989d145bc12cf72f77af5bf1d7191\" target=\"_blank\">Conference call</a> at 8:30 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418440-walgreens-boots-q1-revenues-10-percent-non-gaap-eps-14-percent\" target=\"_blank\">Walgreens Boots Q1 revenues up 10%; non-GAAP EPS up 14%</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418442\" data-linked=\"Walgreens Boots -2.4% after Q1 report, new cost-savings program launched\" data-tweet=\"$WBA - Walgreens Boots -2.4% after Q1 report, new cost-savings program launched https://seekingalpha.com/news/3418442-walgreens-bootsminus-2_4-after-q1-report-new-cost-savings-program-launched?source=tweet\" data-url=\"https://seekingalpha.com/news/3418442-walgreens-bootsminus-2_4-after-q1-report-new-cost-savings-program-launched\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418436\" data-ts=\"1545309492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418436-astrazenecas-lynparza-successful-in-late-stage-study-in-third-line-ovarian-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s Lynparza successful in late-stage study in third-line ovarian cancer</a></h4><ul><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) and collaboration partner Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) <a href=\"https://seekingalpha.com/pr/17363751-lynparza-olaparib-meets-primary-endpoint-phase-3-solominus-3-trial-treatment-relapsed-brca\" target=\"_blank\">announce </a>positive results from an open-label Phase 3 clinical trial, SOLO-3, evaluating Lynparza (olaparib) in 266 patients with relapsed ovarian cancer after two or more lines of treatment. The trial met the primary endpoint of objective response rate and the key secondary endpoint of progression-free survival.</li><li>The trial, the fourth successful late-stage study supporting the PARP inhibitor, was conducted as a post-approval commitment to the FDA.</li><li>AZN is up <font color=\"green\">2%</font> premarket on light volume. MRK is down <font color=\"red\">1%</font> on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418436\" data-linked=\"AstraZeneca&#39;s Lynparza successful in late-stage study in third-line ovarian cancer\" data-tweet=\"$AZN $AZN $MRK - AstraZeneca&#39;s Lynparza successful in late-stage study in third-line ovarian cancer https://seekingalpha.com/news/3418436-astrazenecas-lynparza-successful-in-late-stage-study-in-third-line-ovarian-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3418436-astrazenecas-lynparza-successful-in-late-stage-study-in-third-line-ovarian-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418440\" data-ts=\"1545309481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBA\" target=\"_blank\">WBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418440-walgreens-boots-q1-revenues-up-10-non-gaap-eps-up-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Walgreens Boots Q1 revenues up 10%; non-GAAP EPS up 14%</a></h4><ul><li>Walgreens Boots (<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>) <a href=\"https://seekingalpha.com/pr/17363810-walgreens-boots-alliance-reports-fiscal-2019-first-quarter-results\" target=\"_blank\">Q1 result</a>s: Revenues: $33,793M (+9.9%); Retail Pharmacy USA: $25,721M (+14.4%); Retail Pharmacy International: $2,901M (-5.9%); Pharmaceutical Wholesale: $5,708M (-0.2%).</li><li>Net Income: $1,123M (+36.8%); EPS: $1.18 (+45.7%); Non-GAAP EPS: $1.46 (+14.1%); Non-GAAP Net Income: $1,386M (+7.0%); Quick Assets: $980M (+24.8%); CF Ops: $460M (-54.1%).</li><li><strong>FY2019 Guidance</strong>: Non-GAAP EPS: growth of 7% to 12%.</li><li>Shares are down <font color=\"red\">2%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418440\" data-linked=\"Walgreens Boots Q1 revenues up 10%; non-GAAP EPS up 14%\" data-tweet=\"$WBA - Walgreens Boots Q1 revenues up 10%; non-GAAP EPS up 14% https://seekingalpha.com/news/3418440-walgreens-boots-q1-revenues-up-10-non-gaap-eps-up-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3418440-walgreens-boots-q1-revenues-up-10-non-gaap-eps-up-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418435\" data-ts=\"1545308940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418435-blackberryplus-3_4-after-q3-beat-reaffirms-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry +3.4% after Q3 beat; reaffirms outlook</a></h4><ul><li>BlackBerry (NYSE:<a href='https://seekingalpha.com/symbol/BB' title='BlackBerry Ltd.'>BB</a>)<font color=\"green\"> rises 3.4%</font> in premarket trading after <a href=\"https://seekingalpha.com/pr/17363788-blackberry-reports-fiscal-year-2019-third-quarter-results\" target=\"_blank\">Q3 adjusted EPS </a>of 5 cents beat the average analyst estimate of 2 cents.</li><li>Posts record high adjusted total software and services revenue of $219M, up 10% Y/Y.</li><li>Reaffirms FY2019 outlook of total software and services revenue growth of 8%-10% Y/Y, positive adjusted EPS, and positive free cash flow.</li><li>Q3 GAAP gross margin of 75.2% vs. 76.7% in Q2 and 74.3% in year-ago quarter.</li><li><a href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=2332921-1&amp;h=1011497678&amp;u=http%3A%2F%2Fca.blackberry.com%2Fcompany%2Finvestors%2Fevents.html&amp;a=http%3A%2F%2Fca.blackberry.com%2Fcompany%2Finvestors%2Fevents.html\" target=\"_blank\">Conference call </a>at 8:00 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418421-blackberry-beats-0_03-beats-revenue\" target=\"_blank\">BlackBerry beats by $0.03, beats on revenue</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418435\" data-linked=\"BlackBerry +3.4% after Q3 beat; reaffirms outlook\" data-tweet=\"$BB - BlackBerry +3.4% after Q3 beat; reaffirms outlook https://seekingalpha.com/news/3418435-blackberryplus-3_4-after-q3-beat-reaffirms-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3418435-blackberryplus-3_4-after-q3-beat-reaffirms-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418434\" data-ts=\"1545308848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTC-USD\" target=\"_blank\">BTC-USD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418434-cryptos-crashing-upward\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cryptos crashing upward</a></h4><ul><li>Tumbling cryptos surely were due for a furious bounce, and they're getting it over the past few sessions. <a href=\"https://seekingalpha.com/news/3418058-signs-crypto-bottom-masters-exits\" target=\"_blank\">This week's exit</a> from the industry of early evangelist Blythe Masters may have rung a bell for at least a temporary bottom.</li><li>Bitcoin (<a href='https://seekingalpha.com/symbol/BTC-USD' title='Bitcoin USD'>BTC-USD</a>) today is <font color=\"green\">up nearly 10%</font> and back above $4K. Bitcoin Cash (<a href='https://seekingalpha.com/symbol/BCH-USD' title='Bitcoin Cash USD'>BCH-USD</a>) is <font color=\"green\">higher by a whopping 35%</font>.</li><li>Others: Ether (<a href='https://seekingalpha.com/symbol/ETH-USD' title='Ethereum USD'>ETH-USD</a>) <font color=\"green\">+10%</font>, Litecoin (<a href='https://seekingalpha.com/symbol/LTC-USD' title='Litecoin USD'>LTC-USD</a>) <font color=\"green\">+8.6%</font>, Ripple (<a href='https://seekingalpha.com/symbol/XRP-USD' title='XRP USD'>XRP-USD</a>) <font color=\"green\">+9.3%</font>.</li><li><a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a> no action premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3418434\" data-linked=\"Cryptos crashing upward\" data-tweet=\"$BTC-USD $BTC-USD $BCH-USD - Cryptos crashing upward https://seekingalpha.com/news/3418434-cryptos-crashing-upward?source=tweet\" data-url=\"https://seekingalpha.com/news/3418434-cryptos-crashing-upward\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>108&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418429\" data-ts=\"1545308374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VXRT\" target=\"_blank\">VXRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418429-vaxart-files-for-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vaxart files for stock offering</a></h4><ul><li>Vaxart (NASDAQ:<a href='https://seekingalpha.com/symbol/VXRT' title='Vaxart, Inc.'>VXRT</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/72444/000151316218000319/forms_3.htm#use\" target=\"_blank\">prospectus</a> for a $25M of common stock offering.</li><li>Shares are down <font color=\"red\">3%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418429\" data-linked=\"Vaxart files for stock offering\" data-tweet=\"$VXRT - Vaxart files for stock offering https://seekingalpha.com/news/3418429-vaxart-files-for-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3418429-vaxart-files-for-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418428\" data-ts=\"1545307993\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418428-astrazeneca-announces-successful-results-from-two-late-stage-roxadustat-studies-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca announces successful results from two late-stage roxadustat studies; shares up 3% premarket</a></h4><ul><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) <a href=\"https://www.astrazeneca.com/media-centre/press-releases/2018/phase-iii-olympus-and-rockies-trials-for-roxadustat-met-their-primary-endpoints-in-chronic-kidney-disease-patients-with-anaemia20122018.html\" target=\"_blank\">announces </a>positive results from two Phase 3 clinical trials, OLYMPUS and ROCKIES, evaluating roxadustat in chronic kidney disease patients with anemia who are either dialysis-dependent (ROCKIES) or not (OLYMPUS).</li><li>Both studies met the primary endpoints. The data will support marketing applications in the U.S. and other major markets.</li><li>Detailed results will be submitted for presentation at future medical conferences.</li><li>Shares are up <font color=\"green\">3%</font> premarket on light volume.</li><li>Related ticker: (NASDAQ:<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418428\" data-linked=\"AstraZeneca announces successful results from two late-stage roxadustat studies; shares up 3% premarket\" data-tweet=\"$AZN $AZN $FGEN - AstraZeneca announces successful results from two late-stage roxadustat studies; shares up 3% premarket https://seekingalpha.com/news/3418428-astrazeneca-announces-successful-results-from-two-late-stage-roxadustat-studies-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3418428-astrazeneca-announces-successful-results-from-two-late-stage-roxadustat-studies-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418421\" data-ts=\"1545307375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418421-blackberry-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry beats by $0.03, beats on revenue</a></h4><ul><li>BlackBerry (NYSE:<a href='https://seekingalpha.com/symbol/BB' title='BlackBerry Ltd.'>BB</a>): Q3 Non-GAAP EPS of $0.05 <span style=\"color:green\">beats by $0.03</span>; GAAP EPS of -$0.01 in-line.</li><li>Revenue of $228M (-3.0% Y/Y) <font color=\"green\">beats by $14.63M</font>.</li><li>Shares <font color=\"green\">+6%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17363788-blackberry-reports-fiscal-year-2019-third-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418421\" data-linked=\"BlackBerry beats by $0.03, beats on revenue\" data-tweet=\"$BB - BlackBerry beats by $0.03, beats on revenue https://seekingalpha.com/news/3418421-blackberry-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3418421-blackberry-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":73,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}